Home Cart Sign in  
Chemical Structure| 444731-52-6 Chemical Structure| 444731-52-6

Structure of Pazopanib
CAS No.: 444731-52-6

Chemical Structure| 444731-52-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50 values of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM, and 146 nM, respectively.

Synonyms: GW786034; GSK-VEG10003; GW786034B

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Marlhoux, Léna ; Arnaud, Alexandre ; Hervieu, Céline ; Makulyte, Gabriela ; Martinasso, Charlotte ; Mularoni, Angélique , et al.

Abstract: Casein kinase 2 (CK2) has emerged as a promising therapeutic target across a broad spectrum of malignancies, including pediatric and orphan cancers. The identification of a ligandable allosteric αD pocket on the CK2α subunit has enabled the development of bivalent inhibitors, which bind simultaneously to both the adenosine triphosphate (ATP) site and the allosteric pocket. Here, we report the discovery and pharmacological characterization of KDX1381, a structure-guided bivalent CK2α inhibitor with low-nanomolar potency and high selectivity, confirmed by cocrystal structures. In mice, KDX1381 suppressed CK2-driven tumor growth as a monotherapy and enhanced therapeutic efficacy when combined with vascular endothelial growth factor receptor (VEGFR) inhibitors or DNA-damaging agents in hepatocellular carcinoma and glioma models. These findings support bivalent CK2α inhibition as a differentiated therapeutic strategy with broad applicability in CK2-dependent cancers.

Alternative Products

Product Details of Pazopanib

CAS No. :444731-52-6
Formula : C21H23N7O2S
M.W : 437.52
SMILES Code : CN(C1=CC=NC(NC2=CC=C(C(S(N)(=O)=O)=C2)C)=N1)C3=CC4=NN(C(C)=C4C=C3)C
Synonyms :
GW786034; GSK-VEG10003; GW786034B
MDL No. :MFCD11616589
InChI Key :CUIHSIWYWATEQL-UHFFFAOYSA-N
Pubchem ID :10113978

Safety of Pazopanib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H413
Precautionary Statements:P264-P270-P273-P301+P312-P330

Related Pathways of Pazopanib

RTK

Isoform Comparison

Biological Activity

Target
  • VEGFR1

    VEGFR1, IC50:10 nM

  • VEGFR3

    VEGFR3, IC50:47 nM

  • VEGFR2

    VEGFR2, IC50:30 nM

  • PDGFR

    PDGFR, IC50:84 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Ren-01 cells 2 µM 24 h To evaluate the effect of Pazopanib on Ren-01 cells, results showed that Pazopanib alone or in combination with MEK inhibitor reduced phosphorylation of MEK1/2 and ERK1/2. PMC5061902
MKN45 cells 10 μM to 100 μM 6 days To evaluate the effect of Pazopanib on epithelial-mesenchymal transition (EMT) in MKN45 cells, results showed that EMT was not induced in vitro. PMC8170833
SKOV3ip1 cells 0.001-100 μM 3-4 h Pazopanib treatment reduced VEGFR-2 phosphorylation, especially at higher doses (≥1 μM). PMC2852465
HeyA8 cells 0.001-100 μM 3-4 h Pazopanib treatment reduced VEGFR-2 phosphorylation, but the effect was more pronounced at higher doses. PMC2852465
MOECs (murine ovarian endothelial cells) 0.001, 1, 10 μM 4-5 h Pazopanib treatment reduced endothelial cell migration in a dose-dependent manner following VEGF stimulation. PMC2852465
786-O cells 8 µM To evaluate the effect of Pazopanib on the proliferation of 786-O cells PMC7153841
Human aortic endothelial cells (HAoEC) 5 µg/mL 3 h Pazopanib abolished the intermittent hypoxia (IH)-induced increase in LDL passage through an endothelial cell monolayer. PMC9266969
Human aortic endothelial cells (HAoEC) 5 µg/mL 4 h Pazopanib abolished the intermittent hypoxia (IH)-induced monocyte migration through an endothelial cell monolayer. PMC9266969
Daoy cells 15 μM 24 h Pazopanib reduced the migratory capacity of Daoy cells and altered cell morphology, leading to decreased cell-cell connections and a more spindle-shaped phenotype. PMC9716228
MEB-Med-8A cells 15 μM 12 h Pazopanib reduced the migratory capacity of MEB-Med-8A cells and caused morphological changes, leading to decreased cell-cell connections and loss of adhesive properties. PMC9716228
HCT116 cells 10 nM 14-16 h Inhibition of the kinase function of VEGFR1 by pazopanib or SU5416 also had no effect on pAKT or pERK1/2 levels PMC4873444
SW480 cells 10 nM 14-16 h Inhibition of the kinase function of VEGFR1 by pazopanib or SU5416 also had no effect on pAKT or pERK1/2 levels PMC4873444
HT29 cells 10 nM 14-16 h Inhibition of the kinase function of VEGFR1 by pazopanib or SU5416 also had no effect on pAKT or pERK1/2 levels PMC4873444

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice SNU5 gastric carcinoma xenograft model Oral 100 mg/kg Once daily for 8 days To study the effect of pazopanib on MET signaling, results showed that pazopanib increased the pY1235-MET:MET and pY1356-MET:MET ratios, and tivantinib reversed this effect. PMC7802886
Mice Ren-02 renal cell carcinoma xenograft model Oral 100 mg/kg Twice daily, until the end of the experiment To evaluate the anti-tumor effect of Pazopanib in a renal cell carcinoma xenograft model, results showed that Pazopanib alone or in combination with MEK inhibitor reduced phosphorylation of MEK1/2 and ERK1/2 and inhibited tumor growth. PMC5061902
Nude mice MKN45 and SNU5 gastric cancer xenograft models Oral 100 mg/kg Once daily for 14 days (MKN45) or 15 days (SNU5) To evaluate the effect of Pazopanib on epithelial-mesenchymal transition (EMT) in gastric cancer xenograft models, results showed a significant shift toward a mesenchymal phenotype in pazopanib-treated MKN45 xenografts, while the SNU5 model showed no significant changes. PMC8170833
Mice Rag2−/−IL2rg−/− double knockout mice Oral gavage 30mg/kg Once daily, continuous treatment Evaluating the efficacy of Pazopanib in ccRCC patient-derived xenograft models, results showed that Pazopanib alone did not significantly affect tumor progression, but when combined with sAXL, it significantly reduced tumor growth and vessel density. PMC7015045
Nude mice SKOV3ip1 and HeyA8 ovarian cancer models Oral 100 mg/kg Every other day, continued until mice became moribund Single agent pazopanib therapy reduced tumor weight by 82% in the SKOV3ip1 model and 28% in the HeyA8 model. Combination therapy with metronomic topotecan resulted in a 79-84% reduction in tumor weight. PMC2852465
Mice C57BL/6J mice Gavage 30 mg/kg Once daily for 14 days Pazopanib prevented the intermittent hypoxia (IH)-induced VE-cadherin cleavage and aortic wall thickening. PMC9266969

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01027598 Non Small Cell Lung Cancer Phase 2 Completed - United States, Florida ... More >> Florida Cancer Specialists Fort Myers, Florida, United States, 33901 United States, Georgia Suburban Hem Onc Lawrenceville, Georgia, United States, 30045 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, South Carolina South Carolina Oncology Associates, PA Columbia, South Carolina, United States, 29210 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Family Cancer Center Collerville, Tennessee, United States, 38119 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Virginia Virginia Cancer Institute Richmond, Virginia, United States, 23235 Less <<
NCT01027598 - Completed - -
NCT01407562 Unspecified Adult Solid Tumor ... More >>- Protocol Specific Breast Cancer - Female Less << Phase 1 Active, not recruiting June 2019 United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Less <<
NCT01280201 Advanced/Metastatic Neuroendoc... More >>rine Tumors Less << PHASE2 COMPLETED 2015-03-15 Institut Català d'Oncologia L'... More >>Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain Less <<
NCT01391611 Gastrointestinal Stromal Tumor... More >> (GIST) Less << PHASE2 TERMINATED 2025-12-13 Stanford University School of ... More >>Medicine, Stanford, California, 94305, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT02348398 Cervical Cancer Phase 2 Withdrawn - -
NCT00350727 Glioma Phase 2 Completed - -
NCT01391611 Gastrointestinal Stromal Tumor... More >> (GIST) Less << PHASE2 TERMINATED 2025-12-13 Stanford University School of ... More >>Medicine, Stanford, California, 94305, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT00370513 Carcinoma, Hepatocellular Phase 1 Completed - United States, California ... More >> GSK Investigational Site San Francisco, California, United States, 94115 Hong Kong GSK Investigational Site Hong Kong, Hong Kong Taiwan GSK Investigational Site Taipei, Taiwan, 100 Less <<
NCT00350727 - Completed - -
NCT00387205 Carcinoma, Renal Cell PHASE1 COMPLETED 2018-03-08 Novartis Investigative Site, D... More >>uarte, California, 91010, United States|Novartis Investigative Site, Santa Monica, California, 90404, United States|Novartis Investigative Site, Aurora, Colorado, 80045, United States|Novartis Investigative Site, Indianapolis, Indiana, 46202, United States|Novartis Investigative Site, Detroit, Michigan, 48201, United States|Novartis Investigative Site, Minneapolis, Minnesota, 55404, United States|Novartis Investigative Site, Lebanon, New Hampshire, 03756, United States|Novartis Investigative Site, New Brunswick, New Jersey, 08901, United States|Novartis Investigative Site, Buffalo, New York, 14263, United States|Novartis Investigative Site, Durham, North Carolina, 27710, United States|Novartis Investigative Site, Cleveland, Ohio, 44106, United States|Novartis Investigative Site, Greenville, South Carolina, 29605, United States|Novartis Investigative Site, Nashville, Tennessee, 37203, United States|Novartis Investigative Site, Houston, Texas, 77030-4009, United States|Novartis Investigative Site, Tacoma, Washington, 98405, United States|Novartis Investigative Site, Lyon Cedex 08, 69373, France|Novartis Investigative Site, Singapore, 119074, Singapore|Novartis Investigative Site, Sutton, Surrey, SM2 5PT, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, NE7 7DN, United Kingdom Less <<
NCT00334282 - Completed - -
NCT00334282 Carcinoma, Renal Cell Phase 3 Completed - -
NCT00866528 Lung Cancer, Non-Small Cell Phase 1 Completed - United States, Illinois ... More >> GSK Investigational Site Chicago, Illinois, United States, 60637 United States, Ohio GSK Investigational Site Columbus, Ohio, United States, 43210 United Kingdom GSK Investigational Site Sutton, Surrey, United Kingdom, SM2 5PT GSK Investigational Site Newcastle upon Tyne, United Kingdom, NE7 7DN Less <<
NCT00459381 Adult Giant Cell Glioblastoma ... More >> Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor Less << Phase 2 Completed - United States, California ... More >> University of California Los Angeles Los Angeles, California, United States, 90095 University of California San Francisco San Francisco, California, United States, 94115 United States, Maryland National Cancer Institute Neuro-Oncology Branch Bethesda, Maryland, United States, 20814 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792 Less <<
NCT01524848 Gastrointestinal Stromal Tumor... More >>s Less << PHASE2 COMPLETED 2025-11-16 Aarhus University Hospital, de... More >>pt. of Oncology, Aarhus, DK-8000 Aarhus C, Denmark|Herlev Hospital, dept. of Oncology, Herlev, 2730, Denmark|Helsinki University Hospital, dept. of oncology, Helsingfors, FI-00029, Finland|Kuopio University Hospital Cancer Center, Kuopio, FI-70029, Finland|Klinik für Interdisziplin?re Onkologie, Sarkomzentrum Berlin-Brandenburg, Berlin, 13125, Germany|Universit?tsklinikum Essen, Innere klinik und Poliklinik, Essen, DE-45122, Germany|Studienzentrale chirurgische klinik, Universit?ts medizin Mannheim, Mannheim, DE-68167, Germany|Dept of Oncology, Haukeland University Hospital, Bergen, N-5021, Norway|Norwegian Radium Hospital, Oslo, N-0310, Norway|Dept of Oncology, St Olav Hospital, Trondheim, N-7006, Norway|Dept of Oncology, Sahlgrenska University Hospital, Gothenburg, SE-413 45, Sweden|Dept of Oncology, Link?ping University Hospital, Link?ping, SE-581 85, Sweden|Dept of Oncology, Skane University Hospital, Lund, SE-221 85, Sweden|Radiumhemmet, Karolinska University Hospital, Stockholm, SE-171 76, Sweden|Dept of Oncology, Norrland University Hospital, Ume?, SE-901 85, Sweden|Dept of Oncology, Academic Hospital, Uppsala, SE-751 85, Sweden Less <<
NCT01548144 Advanced Cancers Phase 1 Active, not recruiting April 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00459381 - Completed - -
NCT01566747 Renal Cell Carcinoma PHASE2 COMPLETED 2020-07-15 Beaumont Hospital, Dublin, Lei... More >>nster, Ireland|Mater Misericordiae University Hospital, Dublin, Leinster, Ireland|Mater Private Hospital, Dublin, Leinster, Ireland|Cork University Hospital, Cork, Ireland|The Adelaide & Meath Hospital Dublin incorporating the National Children's Hospital, Dublin, Ireland|Galway University Hospital, Galway, Ireland|Mid-Western Regional Hospital, Limerick, Ireland|Waterford Regional Hospital, Waterford, Ireland|Karolinska University Hospital, Stockholm, Sweden Less <<
NCT00401583 Carcinoma, Renal Cell Phase 1 Completed - United States, New Hampshire ... More >> GSK Investigational Site Lebanon, New Hampshire, United States, 03756 Singapore GSK Investigational Site Singapore, Singapore, 119074 Less <<
NCT01442662 Leiomyosarcoma Phase 2 Unknown September 2017 France ... More >> Institut de Cancérologie de l'Ouest/Cantre Paul Papin Recruiting Angers, France, 49933 Contact: Patrick Soulie, MD    33 2 41 35 27 00    patrick.soulie@ico.unicancer.fr    Principal Investigator: Patrick Soulie, MD          Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Binh Bui Nguyen, MD    33 5 56 33 38 13    bui@bergonie.org    Principal Investigator: Binh Bui Nguyen, MD          Centre François Baclesse Recruiting Caen, France, 14076 Contact: Corinne Delcambre, MD    33 2 31 45 51 24    c.delcambre@baclesse.fr    Principal Investigator: Corinne Delcambre, MD          Centre Jean Perrin Recruiting Clermont Ferrand, France, 63011 Contact: Jacques-Olivier Bay, Pr    33 4 73 27 80 80    jacques-olivier.bay@cjp.fr    Principal Investigator: Jacques-Olivier Bay, Pr          Centre G.F Leclerc Recruiting Dijon, France, 21034 Contact: Nicolas Isambert, MD    33 3 80 73 75 28    nisambert@cgfl.fr    Principal Investigator: Nicolas Isambert, MD          Centre Oscar Lambret Recruiting Lille, France, 59020 Contact: Nicolas Penel, MD    33 3 20 29 59 59 ext 7956    n-penel@o-lambret.fr    Principal Investigator: Nocolas Penel, MD          Centre Léon Bérard Recruiting Lyon, France, 69373 Contact: Isabelle Ray-Coquard, MD    04 78 78 27 72    ray@lyon.fnclcc.fr    Principal Investigator: Isabelle Ray-Coquard, MD          Institut Paoli Calmettes Not yet recruiting Marseille, France, 13273 Contact: François Bertucci, Pr    33 4 91 22 35 37    bertuccif@marseille.fnclcc.fr    Principal Investigator: François Bertucci, Pr          CHU Timone Recruiting Marseille, France, 13385 Contact: Florence Duffaud, MD    33 4 91 38 57 08    florence.duffaud@mail.ap-hm.fr    Principal Investigator: Florence Duffaud, MD          Centre Val d'Aurelle Paul Lamarque Recruiting Montpellier, France, 34298 Contact: Didier Cupissol, MD    33 4 67 61 81 83    dcupissol@valdorel.fnclcc.fr    Principal Investigator: Didier Cupissol, MD          Institut de Cancérologie de l'Ouest/Centre René Gauducheau Recruiting NANTES Saint Herblain, France, 44806 Contact: Emmanuelle Bompas, MD    33 2 40 67 99 76    emmanuelle.bompas@ico.unicancer.fr    Principal Investigator: Emmanuelle Bompas, MD          Centre Antoine Lacassagne Recruiting Nice, France, 06189 Contact: Antoine Thyss, Pr    33 4 92 03 15 38    antoine.thyss@nice.fnclcc.fr    Principal Investigator: Antoine Thyss, Pr          Institut Curie - Hôpital Claudius Regaud Recruiting Paris, France, 75005 Contact: Sophie Piperno- Neumann, MD    33 1.44.32.46.81    sophie.piperno-neumann@curie.net    Principal Investigator: Sophie Piperno-Neumann, MD          Institut Jean Godinot Recruiting Reims, France, 51056 Contact: Jean-Christophe Eymard, MD    33 3.26.50.43.92    jc.eymard@reims.fnclcc.fr    Principal Investigator: Jean-Christophe Eymard, MD          Centre Henri Becquerel Recruiting Rouen, France, 76038 Contact: Cécile Guillemet, MD    33 2 32 08 22 38    C.Guillemet@rouen.fnclcc.fr    Principal Investigator: Cécile Guillemet, MD          Institut Curie - Hopital René Huguenin Recruiting Saint Cloud, France, 92210 Contact: Etienne Brain, MD    33 1 47 11 15 15 ext 18.75    etienne.brain@curie.net    Principal Investigator: Etienne Brain, MD          Institut de Cancérologie de la Loire Recruiting St Priest en jarez, France, 42270 Contact: Olivier Collard, MD    33 4 77 91 70 34    olivier.collard@icloire.fr    Principal Investigator: Olivier Collard, MD          Centre Paul Strauss Not yet recruiting Strasbourg, France, 67065 Contact: Thierry Petit, Pr    33 3.88.25.24.56    tpetit@strasbourg.fnclcc.fr    Principal Investigator: Thierry Petit, Pr          Institut Claudius Regaud Recruiting Toulouse, France, 31052 Contact: Christine Chevreau, MD    05 61 42 41 74    chevreau.christine@claudiusregaud.fr    Principal Investigator: Christine Chevreau, MD          Centre Alexis Vautrin Recruiting Vandoeuvre les Nancy, France, 54511 Contact: Maria Rios, MD    33 3 83 59 83 31    m.rios@nancy.fnclcc.fr    Principal Investigator: Maria Rios, MD          Institut Gustave Roussy Recruiting Villejuif, France, 94805 Contact: Patricia Pautier, MD    33 1 42 11 45 17    pautier@igr.fr    Principal Investigator: Patrica Pautier, MD Less <<
NCT02691767 Refractory Solid Tumors Not Applicable Unknown December 2018 Korea, Republic of ... More >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 Less <<
NCT02307474 Clear Cell Renal Cell Carcinom... More >>a Renal Cell Carcinoma Less << Not Applicable Withdrawn(Funding Unavailable) - United States, Ohio ... More >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less <<
NCT03334409 Clear Cell Renal Cell Carcinom... More >>a Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v7 Less << Phase 2 Recruiting June 1, 2021 United States, Florida ... More >> Mayo Clinic in Florida Not yet recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Caroline Merillat    904-953-3237    Merillat.Caroline@mayo.edu    Principal Investigator: Richard W. Joseph          United States, Illinois Illinois CancerCare-Peoria Recruiting Peoria, Illinois, United States, 61615 Contact: Carrie Geoffroy    309-243-3000    cgeoffroy@illinoiscancercare.com    Principal Investigator: Madhuri Bajaj          United States, Iowa Iowa-Wide Oncology Research Coalition NCORP Recruiting Des Moines, Iowa, United States, 50309 Contact: Andrea Zarling    515-241-3305    aczarling@iora.org    Principal Investigator: Joshua C. Lukenbill          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referrals Office    855-776-0015       Principal Investigator: Lance C. Pagliaro          Metro Minnesota Community Oncology Research Consortium Recruiting Saint Louis Park, Minnesota, United States, 55416 Contact: Elizabeth J. Wagner    952-993-1555    elizabeth.wagner@parknicollet.com    Principal Investigator: David King          United States, North Dakota Sanford Medical Center Fargo Not yet recruiting Fargo, North Dakota, United States, 58104 Contact: Melissa Burgard    701-234-2718    melissa.burgard@sanfordhealth.org    Principal Investigator: Preston D. Steen          United States, Ohio Columbus NCI Community Oncology Research Program Not yet recruiting Columbus, Ohio, United States, 43215 Contact: Deborah A. Shaw    614-488-3310    debby@columbusccop.org    Principal Investigator: Timothy D. Moore Less <<
NCT01855724 Cholangiocarcinoma ... More >> Gallbladder Carcinoma Biliary Carcinoma Less << Phase 2 Terminated - Greece ... More >> 2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital Athens, Greece, 11522 Dept of Medical Oncology, 251 General Air Force Hospital Athens, Greece, 11525 2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio" Athens, Greece, 11527 Oncology Dept, 2nd Surgyc Clinic, Aretaieio Hospital Athens, Greece, 11528 Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra" Athens, Greece, 11528 Division of Oncology, 2nd Dept of Internal Medicine, Propaedeutic, University Hospital "Attikon" Athens, Greece, 12462 2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital Athens, Greece, 14564 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital Athens, Greece, 14564 3rd Dept of Medical Oncology, Hygeia Hospital Athens, Greece, 15123 1st Dept of Medical Oncology, Metropolitan Hospital Athens, Greece, 18547 2nd Dept of Medical Oncology, Metropolitan Hospital Athens, Greece, 18547 Dept of Medical Oncology, University Hospital of Heraklion Heraklion, Greece, 71110 Dept of Medical Oncology, Ioannina University Hospital Ioannina, Greece, 45500 Division of Oncology, Dept of Internal Medicine, University Hospital of Patras Patras, Greece, 26504 Dept of Medical Oncology, Papageorgiou General Hospital Thessaloniki, Greece, 56429 Dept of Medical Oncology, Thermi Clinic S.A Thessaloniki, Greece, 57001 2nd Dept of Medical Oncology, EUROMEDICA General Clinic of Thessaloniki Thessaloníki, Greece, 54645 Less <<
NCT01247571 Recurrent Uterine Corpus Sarco... More >>ma Uterine Carcinosarcoma Less << Phase 2 Completed - -
NCT01247571 - Completed - -
NCT01513187 Advanced Renal Cell Carcinoma Phase 1 Phase 2 Active, not recruiting October 2018 Spain ... More >> Instituto Catalán de Oncología, Hospitalet del Llobregat Hospitalet de Llobregat, Barcelona, Spain, 08097 Centro Integral Oncológico Clara Campal Sanchinarro, Sanchinarro - Madrid, Spain, 28050 Hospital del Mar Barcelona, Spain, 08003 Hospital Clínic Barcelona, Spain, 08036 Hospital Clínico San Carlos Madrid, Spain, 28040 Hospital Universitario 12 de Octubre Madrid, Spain, 28041 Hospital Central de Asturias Oviedo, Spain, 33066 Hospital Son Espases Palma, Spain, 07010 Clinica Univ. Navarra Pamplona, Spain, 31008 Hospital Virgen de la Macarena Sevilla, Spain, 41009 Hospital Virgen del Rocio Sevilla, Spain, 41013 Hospital Virgen de la Salud Toledo, Spain, 45004 IVO Valencia, Spain, 46009 Less <<
NCT00731211 Renal Cell Carcinoma PHASE2 COMPLETED 2025-09-12 San Francisco Oncology Associa... More >>tes, San Francisco, California, 94115, United States|Florida Cancer Specialists, Fort Myers, Florida, 33901, United States|Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, 33805, United States|Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, 33705, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, 30901, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Baptist Hospital East, Louisville, Kentucky, 40207, United States|Central Maine Medical Center, Lewiston, Maine, 04240, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, 49503, United States|St. Louis Cancer Care, Chesterfield, Missouri, 63017, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, 29210, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37023, United States|Virginia Cancer Institute, Richmond, Virginia, 23235, United States Less <<
NCT00731211 Renal Cell Carcinoma PHASE2 COMPLETED 2025-09-12 San Francisco Oncology Associa... More >>tes, San Francisco, California, 94115, United States|Florida Cancer Specialists, Fort Myers, Florida, 33901, United States|Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, 33805, United States|Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, 33705, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, 30901, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Baptist Hospital East, Louisville, Kentucky, 40207, United States|Central Maine Medical Center, Lewiston, Maine, 04240, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, 49503, United States|St. Louis Cancer Care, Chesterfield, Missouri, 63017, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, 29210, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37023, United States|Virginia Cancer Institute, Richmond, Virginia, 23235, United States Less <<
NCT01059656 Dermatofibrosarcomas of DARIER... More >> FERRAND(DFSP) Less << PHASE2 TERMINATED 2025-04-14 H?pital Saint-Louis - Service ... More >>de Dermatologie (Pole POPS), Paris, 75010, France Less <<
NCT01639911 Malignant Neoplasm of Breast ... More >> CNS Malignancy Malignant Neoplasm of Gastrointestinal Tract Genitourinary Neoplasms Malignancy and Gender Unspecified Head and Neck Neoplasms Melanoma Malignant Neoplasm of Thorax Less << Phase 1 Completed - United States, Illinois ... More >> University of Illinois Cancer Center Chicago, Illinois, United States, 60612 Less <<
NCT01995981 Sarcoma, Soft Tissue COMPLETED 2017-11-10 Radboud University Nijmegen Me... More >>dical Centre, Nijmegen, 6525 GA, Netherlands|Royal Marsden Hospital, London, United Kingdom Less <<
NCT01165385 Solid Tumors ... More >>Metastatic Cancer Less << Phase 1 Completed - France ... More >> Centre François BACLESSE Caen, France, 14076 Centre Georges François LECLERC Dijon, France, 21079 Centre Léon Berard Lyon, France, 69373 CEDEX 08 Centre René Gauducheau Nantes Saint Herblain, France, 44805 Institut Curie Paris, France, 75248 Less <<
NCT01713296 SCLC PHASE2 COMPLETED 2025-03-15 "Agioi Anargyroi" Anticancer H... More >>ospital of Athens, Athens, Greece|"IASO" General Hospital of Athens, Athens, Greece|401 Military Hospital of Athens, Athens, Greece|Air Forces Military Hospital of Athens, Athens, Greece|University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece, Heraklion, Greece|"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece|"Papageorgiou" Hospital of Thessaloniki, Thessaloniki, Greece|"Theagenion" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, Greece Less <<
NCT01552356 Solid Neoplasm Phase 1 Active, not recruiting - United States, Florida ... More >> Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT02383251 Ovarian Cancer Phase 2 Recruiting December 2018 France ... More >> ICO Paul Papin Active, not recruiting Angers, France, 49933 Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Anne Floquet, MD    5 56 33 33 33 ext 033    a.floquet@bordeaux.unicancer.fr    Polyclinique Bordeaux Nord Active, not recruiting Bordeaux, France, 33300 Centre François Baclesse Recruiting Caen, France, 14000 Contact: Emmanuel Sevin, MD    2 31 45 53 97 ext 0033    e.sevin@baclesse.unicancer.fr    Centre Jean Perrin Active, not recruiting Clermont-ferrand, France, 63000 Centre Hospitalier de Dax Enrolling by invitation Dax, France, 40107 Centre Georges François Leclerc Active, not recruiting Dijon, France, 21079 Hôpital André Mignot Recruiting Le Chesnay, France, 78157 Contact: Didier MAYEUR, MD    1 39 63 91 33 ext 0033    dmayeur@ch-versailles.fr    Centre Jean Bernard - Clinique Victor Hugo Recruiting Le Mans, France, 72000 Contact: Hugues BOURGEOIS, MD    2 43 47 94 94 ext 0033    h.bourgeois@cjb72.org    Centre Oscar Lambret Active, not recruiting Lille, France, 59200 Centre Léon Bérard Enrolling by invitation Lyon, France, 69373 Institut Paoli Calmettes Recruiting Marseille, France, 13009 Contact: Magali PROVANSAL, MD    4 91 22 37 40 ext 0033    provansalm@ipc.unicancer.fr    Hôpital de Mont-de-Marsan Active, not recruiting Mont-de-marsan, France, 40024 ICM Val d'Aurelle Recruiting Montpellier, France, 34298 Contact: Michel FABBRO, MD    4 67 61 30 63 ext 0033    michel.fabbro@icm.unicancer.fr    ORACLE - Centre d'Oncologie de Gentilly Recruiting Nancy, France, 54100 Contact: Dominique SPAETH, MD    3 83 93 50 05 ext 0033    oncomed@wanadoo.fr    Centre Catherine de Sienne Recruiting Nantes, France, 44202 Contact: Alain LORTHOLARY, MD    2 28 27 21 71 ext 0033    lortholary.alain@catherinedesienne.fr    Centre Antoine Lacassagne Enrolling by invitation Nice, France, 06189 Centre Hospitalier Régional d'Orléans Active, not recruiting Orléans, France, 45067 Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Cochin Active, not recruiting Paris, France, 75014 Clinique Francheville Active, not recruiting Perigueux, France, 20004 Centre Hospitalier Lyon Sud Recruiting Pierre Benite, France, 69495 Contact: Benoît YOU, MD    4 78 86 43 18 ext 0033    benoit.you@chu-lyon.fr    Hôpital Privé des Côtes d'Armor Recruiting Plerin Sur Mer, France, 22190 Contact: Anne-Claire HARDY-BESSARD, MD    2 96 75 22 16 ext 0033    ac.hardy@clin-armoricaine.fr    "Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers - Pôle Régional de Cancérologie" Enrolling by invitation Poitiers, France, 86021 ICO Centre René Gauducheau Active, not recruiting Saint-herblain, France, 44805 Hôpitaux Universitaires de Strasbourg Enrolling by invitation Strasbourg, France, 67000 Centre Paul Strauss Active, not recruiting Strasbourg, France, 67065 Centre Hospitalier de Thonon-les-Bains Recruiting Thonon-les-Bains, France, 74203 Contact: Francesco DEL PIANO, MD    4 50 83 20 65 ext 0033    f-delpiano@ch-hopitauxduleman.fr    ICL Institut de Cancérologie de Lorraine Recruiting Vandoeuvre-les-nancy, France, 54511 Contact: Marie-Christine KAMINSKY, MD    3 83 59 83 63 ext 0033    mc.kaminsky@nancy.unicancer.fr Less <<
NCT01235962 Cancer Phase 3 Active, not recruiting April 15, 2019 -
NCT01466972 Breast Cancer|Breast Neoplasm PHASE2 COMPLETED 2019-10-02 University of California, San ... More >>Francisco, San Francisco, California, 94143, United States Less <<
NCT01436227 Von Hippel-Lindau Syndrome Phase 2 Active, not recruiting January 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02207309 Sarcoma Phase 2 Terminated(poor recruitment) - Germany ... More >> Ludwig-Maximilians University of Munich, Klinikum Großhadern Munich, Bavaria, Germany, 81377 Less <<
NCT01613846 Renal Cell Carcinoma Phase 3 Completed - -
NCT02367651 Sarcoma, Soft Tissue Phase 2 Withdrawn(Study cancelled With... More >>drawn before enrollment of any participants) Less << May 2018 -
NCT01262820 Lung Cancer PHASE2 COMPLETED 2025-10-14 North Carolina Cancer Hospital... More >> at U of North Carolina at CH, Chapel Hill, North Carolina, 27599, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States Less <<
NCT01262820 Lung Cancer PHASE2 COMPLETED 2025-10-14 North Carolina Cancer Hospital... More >> at U of North Carolina at CH, Chapel Hill, North Carolina, 27599, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States Less <<
NCT03628131 Relapsed Pediatric Solid Tumor... More >> Refractory Pediatric Solid Tumor Less << Phase 1 Phase 2 Not yet recruiting July 2025 Korea, Republic of ... More >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Ki Woong Sung    82-2-3410-3529    kwsped@skku.edu    Principal Investigator: Ki Woong Sung Less <<
NCT00945477 - Terminated(Slow enrollment) - -
NCT00945477 Prostate Cancer Phase 2 Terminated(Slow enrollment) - United States, Illinois ... More >> Illinois CancerCare Bloomington, Illinois, United States, 61701 Illinois CancerCare Ottawa, Illinois, United States, 61350 Illinois CancerCare Pekin, Illinois, United States, 61554 Illinois Cancer Care Peoria, Illinois, United States, 61615 Less <<
NCT01767636 Carcinoma of the Collecting Du... More >>cts of Bellini Chromophobe Renal Cell Carcinoma Kidney Medullary Carcinoma Kidney Oncocytoma Metastatic Renal Cell Cancer Papillary Renal Cell Carcinoma Recurrent Renal Cell Carcinoma Sarcomatoid Renal Cell Carcinoma Stage IV Renal Cell Cancer Less << Phase 2 Active, not recruiting May 16, 2019 United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT02810756 Pharmacokinetics of Pazopanib Early Phase 1 Completed - Netherlands ... More >> Netherlands Cancer Institute Amsterdam, North Holland, Netherlands, 1066 CX Less <<
NCT01179269 Non-small Cell Lung Cancer Phase 2 Withdrawn(The study was stoppe... More >>d because the research team was unable to enroll any participants) Less << - -
NCT01498458 - Completed - -
NCT01238770 Epithelial Ovarian Cancer PHASE1|PHASE2 COMPLETED 2025-10-15 Marienkrankenhaus Hamburg, Ham... More >>burg, 22087, Germany|Universit?ts-Frauenklinik, Heidelberg, 69120, Germany|Klinikum Konstanz Gyn?kologie und Geburtshilfe, Konstanz, 78464, Germany|Universit?tsmedizin der Johannes Gutenberg-Universit?t Mainz Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde, Mainz, 55131, Germany|Universit?tsfrauenklinik Tübingen Klinik für Gyn?kologie und Geburtshilfe, Tübingen, 72076, Germany Less <<
NCT02089802 Locally Advanced Renal Cell Ca... More >>rcinoma|Metastatic Renal Cell Carcinoma Less << PHASE2 TERMINATED 2016-03-22 Gesundheitszentrum Holzminden,... More >> Holzminden, Niedersachsen, 37603, Germany|Private Practice Kamann, Leipzig, Sachsen, 04357, Germany|Private Practice Geiges, Berlin, 10719, Germany Less <<
NCT00929903 Childhood Central Nervous Syst... More >>em Choriocarcinoma Childhood Central Nervous System Embryonal Tumor Childhood Central Nervous System Germ Cell Tumor Childhood Central Nervous System Germinoma Childhood Central Nervous System Mixed Germ Cell Tumor Childhood Central Nervous System Teratoma Childhood Central Nervous System Yolk Sac Tumor Metastatic Childhood Soft Tissue Sarcoma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Central Nervous System Embryonal Tumor Recurrent Childhood Soft Tissue Sarcoma Recurrent Childhood Visual Pathway Glioma Unspecified Childhood Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Illinois Lurie Children's Hospital-Chicago Chicago, Illinois, United States, 60614 United States, Indiana Indiana University Medical Center Indianapolis, Indiana, United States, 46202 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan C S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, New York Columbia University Medical Center New York, New York, United States, 10032 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States, 15224 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 Baylor College of Medicine Houston, Texas, United States, 77030 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Less <<
NCT01543802 Sarcoma, Soft-tissue Phase 2 Unknown June 2018 Germany ... More >> Klinikum Frankfurt-Höchst Recruiting Frankfurt am Main, Germany, 65929 Contact: Hans-Günter Derigs, MD    +49-69-31063320    derigs@klinikumfrankfurt.de    Principal Investigator: Hans-Günter Derigs, MD          German Cancer Research Center, Medical PET Group - Biological Imaging Recruiting Heidelberg, Germany, 69120 Contact: Antonia Prof. Dr. Antonia Dimitrakopoulou-Strauss, MD    +49-6221-422500    a.dimitrakopoulou-strauss@dkfz.de    Principal Investigator: Antonia Antonia Dimitrakopoulou-Strauss, MD          University Hospital Heidelberg / National Centre for Tumor Diseases Recruiting Heidelberg, Germany, 69120 Contact: Gerlinde Egerer, MD    +49-6221-568002    Gerlinde.Egerer@med.uni-heidelberg.de    Principal Investigator: Gerlinde Egerer, MD          Sub-Investigator: Stefan Froehling, MD          University Hospital Mannheim, Dpt. of Surgery Recruiting Mannheim, Germany, 68135 Contact: Ulrich Ronellenfitsch, MD    +49-621-3831501    ulrich.ronellenfitsch@umm.de    Principal Investigator: Peter Hohenberger, MD Less <<
NCT01498458 Metastatic Breast Cancer Phase 1 Completed - Germany ... More >> GBG Forschungs GmbH Neu-Isenburg, Germany, 63263 Less <<
NCT01265940 Advanced Urothelial Cancer of ... More >>Bladder After Failure of Platinum-containing Therapy. Less << Phase 1 Phase 2 Completed - Germany ... More >> Lukaskrankenhaus Neuss, Germany, 41464 Less <<
NCT01064310 Carcinoma, Renal Cell Phase 3 Completed - -
NCT01064310 - Completed - -
NCT01205230 Cancer Phase 4 Completed - United States, New Jersey ... More >> GSK Investigational Site New Brunswick, New Jersey, United States, 08901 United States, South Carolina GSK Investigational Site Greenville, South Carolina, United States, 29605 Less <<
NCT01608009 Ovarian Neoplasm Phase 1 Completed - United Kingdom ... More >> Imperial College Healthcare NHS Trust London, United Kingdom Southend University Hospital NHS Foundation Trust Southend, United Kingdom Less <<
NCT01797874 SCLC Phase 2 Active, not recruiting December 2017 Korea, Republic of ... More >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 Less <<
NCT01330966 Chondrosarcoma ... More >> Metastatic Chondrosarcoma Less << Phase 2 Completed - United States, California ... More >> City of Hope Duarte, California, United States, 91010 United States, Illinois Edward Cancer Center Naperville, Illinois, United States, 60540 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Pennsylvania Pennsylvania Oncology Hematology Associates Philadelphia, Pennsylvania, United States, 19106 United States, Texas MD Anderson Houston, Texas, United States, 77030 United Kingdom University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre Edgbaston, Birmingham, United Kingdom, B15 2TH Less <<
NCT01205230 - Completed - -
NCT01257750 Corneal Neovascularization Phase 1 Phase 2 Completed - United States, Massachusetts ... More >> Massachusetts Eye and Ear Infirmary Boston, Massachusetts, United States, 02114 Less <<
NCT02300545 Sarcoma, Soft Tissue|Soft Tiss... More >>ue Sarcoma Less << PHASE2 COMPLETED 2020-07-11 Mayo Clinic - Phoenix, Phoenix... More >>, Arizona, 85054, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, 32224, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Iowa, Iowa City, Iowa, 52242, United States|Mayo Clinic - Rochester, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, 53792, United States Less <<
NCT01257750 - Completed - -
NCT01692496 Advanced and / or Metastatic L... More >>iposarcoma Less << PHASE2 COMPLETED 2018-03-02 HELIOS Klinikum Berlin-Buch (S... More >>arkomzentrum Berlin-Brandenburg), Berlin, D-10707, Germany|Universit?tsklinikum EssenInnere Klinik (Tumorforschung), Essen, D-45147, Germany|Medizinische Hochschule Hannover (Zentrum Innere Medizin), Hannover, D-30625, Germany|Universit?tsmedizin Mannheim (Sarkomzentrum), Manheim, D-68169, Germany|Klinikum Gro?hadern der LMU Universit?t München (Med. Klinik und Poliklinik II), Munich, D-80336, Germany|Hospital Central de Asturias, Oviedo, Asturias, 33011, Spain|Hospital Universitario de Canarias, La Laguna, Islas Canarias, 38320, Spain|Hospital de Navarra, Pamplona, Navarra, 31008, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, 36204, Spain|Hospital Vall d'Hebrón, Barcelona, 08035, Spain|Hospital 12 de Octubre, Madrid, 28041, Spain|Hospital Universitari Son Espases, Palma de Mallorca, 07010, Spain|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain|Instituto Valenciano de Oncología, Valencia, 46009, Spain|Hospital Miguel Servet, Zaragoza, 50009, Spain Less <<
NCT03200717 Advanced Renal Cell Carcinoma|... More >>Metastatic Renal Cell Carcinoma Less << PHASE2 COMPLETED 2021-08-10 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263, United States|Novartis Investigative Site, Caba, Buenos Aires, C1280AEB, Argentina|Novartis Investigative Site, Graz, 8036, Austria|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, Wien, A-1090, Austria|Novartis Investigative Site, Calgary, Alberta, T2N 4N2, Canada|Novartis Investigative Site, Temuco, Araucania, 4810469, Chile|Novartis Investigative Site, Santiago, 8420383, Chile|Novartis Investigative Site, Brno, Czech Republic, 656 53, Czechia|Novartis Investigative Site, Olomouc, CZE, 775 20, Czechia|Novartis Investigative Site, Paris, 75015, France|Novartis Investigative Site, Strasbourg Cedex, F 67098, France|Novartis Investigative Site, Valenciennes, 59300, France|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Budapest, H 1122, Hungary|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, London, NW3 2QG, United Kingdom|Novartis Investigative Site, Manchester, M20 2BX, United Kingdom|Novartis Investigative Site, Preston, PR2 9HT, United Kingdom Less <<
NCT01506596 Liposarcoma S... More >>urgically Unresectable Liposarcoma Metastatic Liposarcoma Less << Phase 2 Completed - United States, California ... More >> Sarcoma Oncology Center Santa Monica, California, United States, 90403 United States, District of Columbia Washington Cancer Institute Washington, District of Columbia, United States, 20010 United States, Idaho Kootenai Cancer Center Post Falls, Idaho, United States, 83854 United States, Illinois Oncology Specialists, SC Niles, Illinois, United States, 60714 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Pennsylvania Pennsylvania Oncology Hematology Associates Philadelphia, Pennsylvania, United States, 19106 United States, Tennessee West Clinic Memphis, Tennessee, United States, 38120 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01506596 - Completed - -
NCT01339871 Advanced Cancer Phase 1 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02393820 Salivary Gland Carcinoma Phase 2 Unknown August 2018 France ... More >> Institut de Cancérologie de l'Ouest Paul Papin Angers, France, 49933 CHU Bordeaux Bordeaux, France, 33075 Centre Jean Perrin Clermont-Ferrand, France, 63011 Centre Georges François Leclerc Dijon, France, 21079 Centre Oscar Lambret Lille, France, 59020 Centre Léon Bérard Lyon, France, 69373 Centre Val d'Aurelle Paul Lamarque Montpellier, France, 34298 Centre Antoine Lacassagne Nice, France, 06189 Institut Curie Paris, France, 75231 Centre Hospitalier St Joseph Paris, France, 75674 Centre Eugène Marquis Rennes, France, 35042 Institut Curie site St Cloud Saint Cloud, France, 92210 Institut Cancérologie de l'Ouest Saint-herblain, France, 48805 Centre Paul Strauss Strasbourg, France, 67065 Gustave Roussy Villejuif, France, 94 Less <<
NCT01107665 Stage III Melanoma ... More >> Stage IV Melanoma Unresectable Melanoma Less << Phase 2 Active, not recruiting January 2019 United States, California ... More >> Chao Family Comprehensive Cancer Center Orange, California, United States, 92868 Less <<
NCT01130805 Gastric Cancer Phase 2 Completed - Korea, Republic of ... More >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 Less <<
NCT01956669 Solid Tumours PHASE2 COMPLETED 2019-11-05 Novartis Investigative Site, L... More >>ong Beach, California, 90801, United States|Novartis Investigative Site, Madera, California, 93638-8762, United States|Novartis Investigative Site, Orange, California, 92868, United States|Novartis Investigative Site, Palo Alto, California, 94304, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Hartford, Connecticut, 06106, United States|Novartis Investigative Site, Orlando, Florida, 32806, United States|Novartis Investigative Site, Saint Petersburg, Florida, 33701, United States|Novartis Investigative Site, Chicago, Illinois, 60611, United States|Novartis Investigative Site, Indianapolis, Indiana, 46202, United States|Novartis Investigative Site, Minneapolis, Minnesota, 55404, United States|Novartis Investigative Site, Kansas City, Missouri, 64108, United States|Novartis Investigative Site, Saint Louis, Missouri, 63110, United States|Novartis Investigative Site, Hackensack, New Jersey, 07601, United States|Novartis Investigative Site, New York, New York, 10032, United States|Novartis Investigative Site, Chapel Hill, North Carolina, 27599, United States|Novartis Investigative Site, Charlotte, North Carolina, 28203, United States|Novartis Investigative Site, Cincinnati, Ohio, 45229, United States|Novartis Investigative Site, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, Dallas, Texas, 75235, United States|Novartis Investigative Site, Fort Worth, Texas, 76104, United States|Novartis Investigative Site, Houston, Texas, 77030, United States|Novartis Investigative Site, Norfolk, Virginia, 23507, United States|Novartis Investigative Site, Seattle, Washington, 98105, United States|Novartis Investigative Site, Toronto, Ontario, M5G 1X8, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1C5, Canada|Novartis Investigative Site, Praha 5, 150 05, Czechia|Novartis Investigative Site, Paris Cedex 05, 75248, France|Novartis Investigative Site, Budapest, 1094, Hungary|Novartis Investigative Site, Kosice, 041 66, Slovakia|Novartis Investigative Site, Madrid, 28009, Spain Less <<
NCT02066285 Solitary Fibrous Tumor|Extrask... More >>eletal Myxoid Chondrosarcoma Less << PHASE2 COMPLETED 2023-03-24 H. Son Espases, Palma De Mallo... More >>rca, Islas Baleares, Spain|H. Universitario de Canarias, Tenerife, Santa Cruz De Tenerife, 38320, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital La Paz, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain|H. Miguel Servet, Zaragoza, Spain Less <<
NCT01813136 Thyroid Carcinoma Phase 2 Recruiting June 2018 France ... More >> CHU Angers Recruiting Angers, France, 49933 Principal Investigator: Vincent ROHMER, MD          Sub-Investigator: Frédéric ILLOUZ, MD          Sub-Investigator: Sandrine LABOUREAU-SOARES BARBOSA, MD          Sub-Investigator: Patrice RODIEN, MD          CHU Bordeaux Recruiting Bordeaux, France, 33075 Principal Investigator: Alain RAVAUD, MD          Sub-Investigator: Laurence DIGUE, MD          Sub-Investigator: Marine GROSS-GOUPIL, MD          Sub-Investigator: Amandine QUIVY, MD          Sub-Investigator: Denis SMITH, MD          Sub-Investigator: Nathalie TRUFLANDIER, MD          Institut Bergonié Recruiting Bordeaux, France, 33076 Principal Investigator: Yann GODBERT, MD          Sub-Investigator: Françoise BONICHON, MD          Sub-Investigator: Antoine ITALIANO, MD          Centre François Baclesse Recruiting Caen, France, 14076 Principal Investigator: Stéphane BARDET, MD          Sub-Investigator: Renaud CIAPPUCCINI, MD          CHRU Lille Hôpital Claude Huriez Recruiting Lille, France, 59037 Principal Investigator: Christine DOCAO, MD          Sub-Investigator: Maria-Claire MIGAUD, MD          Centre Leon Berard Recruiting Lyon, France, 69373 Principal Investigator: Christelle DE LA FOUCHARDIERE, MD          Hôpital de la Timone APHM Recruiting Marseille, France, 13385 Principal Investigator: Patricia NICCOLI, MD          Sub-Investigator: Charlotte DUPUIS, MD          Centre Antoine Lacassagne Recruiting Nice, France, 06189 Principal Investigator: Danielle BENISVY, MD          Sub-Investigator: Esma SAADA-BOUZID, MD          Hôpital Saint-Louis APHP Recruiting Paris, France, 75010 Principal Investigator: Damien POUESSEL, MD          Sub-Investigator: Stéphane CULINE, MD          Sub-Investigator: Marie-Elisabeth TOUBERT, MD          Sub-Investigator: Cécile CHOUGNET, MD          Hôpital de la Pitié Salpêtrière APHP Recruiting Paris, France, 75651 Principal Investigator: Johanna WASSERMANN, MD          Sub-Investigator: Laurence LEENHARDT, MD          Sub-Investigator: Jean-Philippe SPANO, MD          Sub-Investigator: Camille BUFFET, MD          Institut Jean Godinot Recruiting Reims, France, 51726 Principal Investigator: Audrey DALAC, MD          Sub-Investigator: Sandrine FIEFFE-COQUET, MD          Sub-Investigator: Jean-Marie POCHART, MD          Sub-Investigator: Claire SCHVARTZ, MD          Institut Claudius Régaud Recruiting Toulouse, France, 31052 Principal Investigator: Slimane ZERDOUD, MD          Sub-Investigator: Jean-Pierre DELORD, MD          Institut Gustave Roussy Recruiting Villejuif, France, 94805 Principal Investigator: Sophie LEBOULLEUX, MD          Sub-Investigator: Eric BAUDIN, MD          Sub-Investigator: Amandine BERDELOU, MD          Sub-Investigator: Martin SCHLUMBERGER, MD Less <<
NCT01649778 Carcinoma, Renal Cell COMPLETED 2017-07-03 Novartis Investigative Site, P... More >>hoenix, Arizona, 85016, United States|Novartis Investigative Site, Orange, California, 92868, United States|Novartis Investigative Site, Jacksonville, Florida, 32256, United States|Novartis Investigative Site, Louisville, Kentucky, 40207, United States|Novartis Investigative Site, Shreveport, Louisiana, 71101, United States|Novartis Investigative Site, Jackson, Mississippi, 39202, United States|Novartis Investigative Site, Lincoln, Nebraska, 68510, United States|Novartis Investigative Site, Henderson, Nevada, 89052, United States|Novartis Investigative Site, Bronx, New York, 10467, United States|Novartis Investigative Site, Charleston, South Carolina, 29414, United States|Novartis Investigative Site, Sioux Falls, South Dakota, 57105, United States|Novartis Investigative Site, Austin, Texas, 78705, United States|Novartis Investigative Site, Dallas, Texas, 75246, United States|Novartis Investigative Site, Fort Worth, Texas, 76104, United States|Novartis Investigative Site, Houston, Texas, 77024, United States|Novartis Investigative Site, Berazategui, Buenos Aires, B1880BBF, Argentina|Novartis Investigative Site, Cordoba, Córdova, X5006HBF, Argentina|Novartis Investigative Site, Rosario, Santa Fe, S2000KZE, Argentina|Novartis Investigative Site, Cordoba, X5004FHP, Argentina|Novartis Investigative Site, San Miguel de Tucuman, T4000IAK, Argentina|Novartis Investigative Site, Santa Fe, 3000, Argentina|Novartis Investigative Site, Hall in Tirol, 6060, Austria|Novartis Investigative Site, Innsbruck, 6020, Austria|Novartis Investigative Site, Leoben, 8700, Austria|Novartis Investigative Site, Linz, 4021, Austria|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, St.Veit/Glan, 9300, Austria|Novartis Investigative Site, Voecklabruck, 4840, Austria|Novartis Investigative Site, Wien, 1090, Austria|Novartis Investigative Site, Wien, 1220, Austria|Novartis Investigative Site, Antwerpen, 2020, Belgium|Novartis Investigative Site, Arlon, 6700, Belgium|Novartis Investigative Site, Bonheiden, 2820, Belgium|Novartis Investigative Site, Bouge, 5004, Belgium|Novartis Investigative Site, Brasschaat, 2930, Belgium|Novartis Investigative Site, Edegem, 2650, Belgium|Novartis Investigative Site, Haine Saint Paul, 7100, Belgium|Novartis Investigative Site, Liege, 4000, Belgium|Novartis Investigative Site, Oostende, 8400, Belgium|Novartis Investigative Site, Ottignies, 1340, Belgium|Novartis Investigative Site, Sint-Niklaas, 9100, Belgium|Novartis Investigative Site, Verviers, 4800, Belgium|Novartis Investigative Site, Bucaramanga, Colombia|Novartis Investigative Site, Medellin, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Tallinn, 10138, Estonia|Novartis Investigative Site, Tallinn, 13419, Estonia|Novartis Investigative Site, Tartu, 51014, Estonia|Novartis Investigative Site, Helsinki, 00029, Finland|Novartis Investigative Site, Kirchheim, Baden-Wuerttemberg, 73230, Germany|Novartis Investigative Site, Aschaffenburg, Bayern, 63739, Germany|Novartis Investigative Site, Erlangen, Bayern, 91054, Germany|Novartis Investigative Site, Hof, Bayern, 95028, Germany|Novartis Investigative Site, Landshut, Bayern, 84028, Germany|Novartis Investigative Site, Frankfurt, Hessen, 60431, Germany|Novartis Investigative Site, Marburg, Hessen, 35043, Germany|Novartis Investigative Site, Neubrandenburg, Mecklenburg-Vorpommern, 17036, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, 18107, Germany|Novartis Investigative Site, Lehrte, Niedersachsen, 31275, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, 48149, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, 42551, Germany|Novartis Investigative Site, Homburg, Saarland, 66421, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, 39104, Germany|Novartis Investigative Site, Chemnitz, Sachsen, 09130, Germany|Novartis Investigative Site, Markkleeberg, Sachsen, 04416, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, 24105, Germany|Novartis Investigative Site, Athens, 115 28, Greece|Novartis Investigative Site, Athens, 11522, Greece|Novartis Investigative Site, Patra, 26504, Greece|Novartis Investigative Site, Thessaloniki, 564 29, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Budapest, 1082, Hungary|Novartis Investigative Site, Budapest, 1097, Hungary|Novartis Investigative Site, Budapest, 1122, Hungary|Novartis Investigative Site, Budapest, 1145, Hungary|Novartis Investigative Site, Debrecen, H-4032, Hungary|Novartis Investigative Site, Pecs, 7624, Hungary|Novartis Investigative Site, Szeged, 6720, Hungary|Novartis Investigative Site, Szombathely, 9700, Hungary|Novartis Investigative Site, Veszprem, 8200, Hungary|Novartis Investigative Site, Haifa, 31048, Israel|Novartis Investigative Site, Haifa, 31096, Israel|Novartis Investigative Site, Jerusalem, 91120, Israel|Novartis Investigative Site, Nahariya, 22100, Israel|Novartis Investigative Site, Tel Aviv, 64239, Israel|Novartis Investigative Site, Napoli, Campania, 80131, Italy|Novartis Investigative Site, Modena, Emilia-Romagna, 41100, Italy|Novartis Investigative Site, Roma, Lazio, 00144, Italy|Novartis Investigative Site, Roma, Lazio, 00152, Italy|Novartis Investigative Site, Roma, Lazio, 00168, Italy|Novartis Investigative Site, Cremona, Lombardia, 26100, Italy|Novartis Investigative Site, Milano, Lombardia, 20133, Italy|Novartis Investigative Site, Pavia, Lombardia, 27100, Italy|Novartis Investigative Site, Ashrafieh, 166484, Lebanon|Novartis Investigative Site, Karachi, 74800, Pakistan|Novartis Investigative Site, Albacete, 02006, Spain|Novartis Investigative Site, Badajoz, 06080, Spain|Novartis Investigative Site, Barcelona, 08003, Spain|Novartis Investigative Site, Barcelona, 08035, Spain|Novartis Investigative Site, Barcelona, 08036, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Burgos, 09006, Spain|Novartis Investigative Site, Castellon, 12002, Spain|Novartis Investigative Site, Don Benito/Badajoz, 06400, Spain|Novartis Investigative Site, Guadalajara, 19002, Spain|Novartis Investigative Site, La Coruna, 15006, Spain|Novartis Investigative Site, La Laguna (Santa Cruz De Tenerife), 38320, Spain|Novartis Investigative Site, Leon, 24071, Spain|Novartis Investigative Site, Lleida, 25198, Spain|Novartis Investigative Site, Lugo, 27003, Spain|Novartis Investigative Site, Manresa (Barcelona), 08243, Spain|Novartis Investigative Site, Ourense, 32005, Spain|Novartis Investigative Site, Pamplona, 31008, Spain|Novartis Investigative Site, Sabadell (Barcelona), 08208, Spain|Novartis Investigative Site, Salamanca, 37007, Spain|Novartis Investigative Site, San Sebastian, 20014, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, 38010, Spain|Novartis Investigative Site, Santiago de Compostela, 15706, Spain|Novartis Investigative Site, Soria, 42002, Spain|Novartis Investigative Site, Valencia, 46009, Spain|Novartis Investigative Site, Valladolid, 47005, Spain|Novartis Investigative Site, Vigo ( Pontevedra), 36204, Spain|Novartis Investigative Site, Zaragoza, 50009, Spain|Novartis Investigative Site, Kaohsiung, 807, Taiwan|Novartis Investigative Site, Kaohsiung, 813, Taiwan|Novartis Investigative Site, Taichung, 40402, Taiwan|Novartis Investigative Site, Taipei, 104, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan Hsien, ROC, Taiwan|Novartis Investigative Site, Ankara, 06500, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, 07059, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, 34365, Turkey|Novartis Investigative Site, Istanbul, 34390, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kayseri, 38039, Turkey|Novartis Investigative Site, Malatya, Turkey|Novartis Investigative Site, Samsun, 55139, Turkey|Novartis Investigative Site, Northwood, Middlesex, HA6 2RN, United Kingdom|Novartis Investigative Site, Birmingham, B9 5SS, United Kingdom|Novartis Investigative Site, Leicester, LE1 5WW, United Kingdom|Novartis Investigative Site, Manchester, M20 4BX, United Kingdom|Novartis Investigative Site, Shrewsbury, SY3 8XQ, United Kingdom Less <<
NCT01253369 Small Cell Lung Cancer|Lung Ca... More >>ncer|SCLC Less << PHASE2 COMPLETED 2025-12-14 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT03592472 Renal Cell Carcinoma Phase 3 Recruiting January 17, 2022 United States, California ... More >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Parikh Mamta          United States, Kentucky Norton Cancer Institute, Norton Healthcare Pavilion Not yet recruiting Louisville, Kentucky, United States, 40202 Contact: Kalebasty Arash          United States, Louisiana Ochsner Clinic Foundation Recruiting New Orleans, Louisiana, United States, 70121 Contact: Matrana Marc          United States, Nebraska GU Research Network/Urology Cancer Center Recruiting Omaha, Nebraska, United States, 68130 Contact: Nordquist Luke          Nebraska Cancer Specialists Recruiting Omaha, Nebraska, United States, 68130 Contact: Hauke Ralph          United States, New York Northwell Health/Monter Cancer Center Recruiting Lake Success, New York, United States, 11042 Contact: Bradley Thomas          United States, Ohio Precision Cancer Research/Dayton Physicians Network - Treatment Recruiting Kettering, Ohio, United States, 45409 Contact: Bane Charles          United States, Pennsylvania St. Luke's Hospital Recruiting Easton, Pennsylvania, United States, 18045 Contact: Faroun Yacoub          United States, Texas HOPE Cancer Center of East Texas Recruiting Tyler, Texas, United States, 75701 Contact: Lee Arielle          United States, Washington Medical Oncology Associates, PS (dba Summit Cancer Centers) Recruiting Spokane, Washington, United States, 99208 Contact: Arvind Chaudhry          Korea, Republic of National Cancer Center - Center For Prostate Cancer Not yet recruiting Goyang-si, Korea, Republic of, 10408 Contact: Jinsoo Chung          CHA Bundang Medical Center, CHA University Not yet recruiting Seongnam-si, Korea, Republic of, 13496 Contact: Chan Kim          Severance Hospital, Yonsei University Health System - Medical Oncology Not yet recruiting Seoul, Korea, Republic of, 03722 Contact: Sun Young Rha          Asan Medical Center - University of Ulsan College of Medicin Not yet recruiting Seoul, Korea, Republic of, 05505 Contact: Jae Lyun Lee          Samsung Medical Center - Hematology-Oncology Not yet recruiting Seoul, Korea, Republic of, 06351 Contact: Se Hoon Park Less <<
NCT01876082 Progressive Desmoids Tumors Phase 2 Recruiting July 2020 France ... More >> Institut Bergonié Recruiting Bordeaux, Aquitaine, France, 33000 Contact: ITALIANO Antoine, MD       a.italiano@bordeaux.unicancer.fr    Principal Investigator: ITALIANO Antoine, MD Less <<
NCT01392352 Renal Cell Carcinoma|Soft Tiss... More >>ue Sarcoma|Glioblastoma|Ovarian Cancer|Cervical Cancer|Breast Cancer|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Pancreatic Cancer|Melanoma|Gastrointestinal Cancer Less << PHASE2 TERMINATED 2025-09-15 Cambridge University Hospitals... More >> NHS Foundation Trust, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom Less <<
NCT01253369 Small Cell Lung Cancer|Lung Ca... More >>ncer|SCLC Less << PHASE2 COMPLETED 2025-12-14 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT01158521 Clear Cell Renal Cell Carcinom... More >>a Stage I Renal Cell Cancer Stage II Renal Cell Cancer Stage III Renal Cell Cancer Less << Phase 2 Completed - United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT01184326 Solid Tumor K... More >>idney Cancer Less << Phase 1 Completed - United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT01158521 - Completed - -
NCT03660930 Soft Tissue Sarcoma Phase 1 Phase 2 Not yet recruiting February 28, 2021 United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Not yet recruiting Seattle, Washington, United States, 98109 Contact: Roxanne Moore    206-606-6425    romoore@seattlecca.org    Principal Investigator: Lee Cranmer, MD Less <<
NCT02203760 Relapsed or Metastatic Uterine... More >> Leiomyosarcomas or Carcinosarcomas Less << Phase 2 Unknown June 2016 Germany ... More >> Praxisklinik für Krebsheilkunde für Frauen Drs. Kittel /Klare / Wetzel Not yet recruiting Berlin, Germany, 10367 Contact: Peter Klare, Dr. med.    +4930/ 5548 9336    info@drklare.de    Contact: Steffen Gläser, Dr. med.          Principal Investigator: Peter Klare, Dr. med.          Sub-Investigator: Steffen Gläser, Dr. med.          Charité Campus Virchow-Klinikum Universitätsmedizin Berlin Not yet recruiting Berlin, Germany, 13353 Contact: Jalid Sehouli, Professor Dr. med.    +4930/ 450 564 002    jalid.sehouli@charite.de    Contact: Radoslav Chekorov, Dr. med.    +4930/450-664399    radoslav.chekerov@charite.de    Principal Investigator: Jalid Sehouli, Prof. Dr. med.          Sub-Investigator: Radoslav Chekorov, Dr. med.          Klinikum Chemnitz gGmbH Frauen- und Kinderklinik Not yet recruiting Chemnitz, Germany, 09116 Contact: Petra Krabisch    4937133322121    p.krabisch@skc.de    Contact: Katja Tittmann       k.tittmann@skc.de    Principal Investigator: Petra Krabisch, Dr. med.          Sub-Investigator: Katja Tittmann, Dr. med.          Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden Klinik für Frauenheilkunde und Geburtshilfe Not yet recruiting Dresden, Germany, 01807 Contact: Ulrich Canzler, Dr. med.    +49351/458-18076    Ulrich.Canzler@uniklinikum-dresden.de    Contact: Karin Kast, Dr. med.    +49351/458-18076       Principal Investigator: Ulrich Canzler, Dr. med.          Sub-Investigator: Karin Kast, Dr. med.          Kliniken-Essen-Mitte Evang. Huyssens-Stiftung Klinik für Senologie / Brustzentrum Not yet recruiting Essen, Germany, 45136 Contact: Phillip Harter, Dr. med.       p.harter@kliniken-essen-mitte.de    Contact: Florian Heitz, Dr. med.       f.heitz@kliniken-essen-mitte.de    Principal Investigator: Phillip Harter, Dr. med.          Sub-Investigator: Florian Heitz, Dr. med.          Universitätsklinikum Freiburg Not yet recruiting Freiburg, Germany, 79106 Contact: Beate Rautenberg, Professor Dr. med.    +49761/ 270-3126    beate.rautenberg@uniklinik-freiburg.de    Contact: Annette Hasenburg, Professor Dr. med.    49761/270-3168    annette.hasenburg@uniklinik-freiburg.de    Principal Investigator: Beate Rautenberg, Prof. Dr. med.          Sub-Investigator: Annette Hasenburg, Prof. Dr. med.          Ernst-Moritz-Arndt-Universität Greifswald (Sauerbruchstr.) Recruiting Greifswald, Germany, 17475 Praxis Prof. Dr. med. Lück / Dr. Schrader / Dr. Noeding Not yet recruiting Hannover, Germany, 30177 Contact: Hans-Joachim Lück, Dr. med.    +49511/ 6 55 52 80    hlueck@goph.de    Contact: Iris Schrader, Dr. med.    +49511/ 65555280    Info@gyn-onko-praxis-hannover.de    Principal Investigator: Hans-Joachim Lück, Dr. med.          Sub-Investigator: Iris Schrader, Dr. med.          Universitätsklinikum Schleswig-Holstein Campus Kiel Klinik für Gynäkologie und Geburtshilfe Not yet recruiting Kiel, Germany Contact: Felix Hilpert, PD Dr.    +49431/597-2047    fhilpert@email.uni-kiel.de    Contact: Elna Kühnle, Dr. med.    +49431/597-2100    elna.k@web.de    Principal Investigator: Felix Hilpert, PD Dr.          Sub-Investigator: Elna Kühnle, Dr. med.          Universitätsklinikum Schleswig-Holstein Campus Lübeck Klinik für Frauenheilkunde und Geburtshilfe (Gynäkologie) Not yet recruiting Lübeck, Germany, 23538 Contact: Lars Hanker, Dr. med.       lars.hanker@uksh.de    Contact: Dörte Lüdders, Dr. med.          Principal Investigator: Lars Hanker, Dr. med.          Sub-Investigator: Dörte Lüdders, Dr. med.          Universitätsklinikum Gießen und Marburg GmbH Klinik für Gynäkologie, gyn. Endokrinologie und Onkologie Not yet recruiting Marburg, Germany, 35043 Contact: Klaus H. Baumann, Dr. med.    496421/5866491    baumannk@med.uni-marburg.de    Contact: Ellen Neubauer          Principal Investigator: Klaus Baumann, Dr. med.          Sub-Investigator: Ellen Neubauer, Dr. med.          Universitätsfrauenklinik Tübingen Not yet recruiting Tübingen, Germany, 72076 Contact: Eva-Maria Grischke, Professor Dr. med.    +497071/ 298 2212    eva-maria.grischke@med.uni-tuebingen.de    Contact: Christian Wieland, Gall          Principal Investigator: Eva-Maria Grischke, Prof. Dr. med.          Sub-Investigator: Christian Wieland Gall, Dr. med.          Universitätsklinikum Ulm Klinik für Frauenheilkunde und Geburtshilfe Not yet recruiting Ulm, Germany, 89075 Contact: Wolfgang Janni, Prof. Dr. med.    +49731 500 58 500    wolfgang.janni@uniklinik-ulm.de    Contact: De Gregorio Nicolaus, Dr. med.    +49731/500 58688    nikolaus.de-gregorio@uniklinik-ulm.de    Principal Investigator: Wolfgang Janni, Prof. Dr. med.          Sub-Investigator: Nicolaus De Gregorio, Dr. med. Less <<
NCT02113826 Metastatic Alveolar Soft Part ... More >>Sarcoma Less << PHASE2 TERMINATED 2025-11-17 Seoul National University Hosp... More >>ital, Seoul, 110-744, Korea, Republic of Less <<
NCT01542047 Cancer, Metastatic Phase 1 Terminated(Low rate of accrual... More >>) Less << - United States, New Mexico ... More >> University of New Mexico Cancer Center Albuquerque, New Mexico, United States, 87131-0001 Less <<
NCT01184326 - Completed - -
NCT02729194 Carcinoma, Renal Cell Early Phase 1 Active, not recruiting April 2020 United States, Michigan ... More >> University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 Less <<
NCT02279576 Penile Squamous Cell Carcinoma... More >> Stage IV Less << Phase 2 Terminated(The low recruitment... More >> of patients will not allow to complete the study with the required number of patients within reasonable time.) Less << - Spain ... More >> Institut Català D'Oncologia L'Hospitalet Hospitalet de Llobregat, Barcelona, Spain, 08908 Complejo Hospitalario de Navarra Pamplona, Navarra, Spain, 31008 Hospital de La Santa Creu I Sant Pau Barcelona, Spain, 08025 Complejo Hospitalario Regional Reina Sofía Córdoba, Spain, 14004 Hospital Universitario Lucus Augusti Lugo, Spain, 27003 Hospital Clínico San Carlos Madrid, Spain, 28040 Hospital General Universitario J.M. Morales Meseguer Murcia, Spain, 30008 Instituto Valenciano de Oncología Valencia, Spain, 46009 Less <<
NCT01072890 Solid Tumors Phase 1 Completed - United States, California ... More >> University of California Davis Cancer Center Sacramento, California, United States, 95817 Less <<
NCT01975519 Advanced Soft Tissue Sarcoma Phase 1 Phase 2 Active, not recruiting March 2020 United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35243 United States, California Sarcoma Oncology Center Santa Monica, California, United States, 90403 United States, Florida Mayo Clinic Jacksonville Jacksonville, Florida, United States, 32224 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 92122 Mount Sinai School of Medicine-Tisch Cancer Institute New York, New York, United States, 10029 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 United States, Texas Mary Crowley Cancer Research Center Dallas, Texas, United States, 75230 United States, Utah University of Utah Salt Lake City, Utah, United States, 84112 Less <<
NCT01361113 Renal Cell Carcinoma PHASE2 COMPLETED 2017-02-15 North Carolina Cancer Hospital... More >> (UNC), Chapel Hill, North Carolina, 27599, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01430572 Advanced Cancers ... More >> Solid Tumors Less << Phase 1 Active, not recruiting October 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01361113 Renal Cell Carcinoma PHASE2 COMPLETED 2017-02-15 North Carolina Cancer Hospital... More >> (UNC), Chapel Hill, North Carolina, 27599, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT02055690 Ovarian Neoplasms ... More >> Neoplasms, Ovarian Ovarian Cancer Less << Phase 1 Phase 2 Terminated(Safety) - United Kingdom ... More >> Royal United Hospital Bath NHS Trust Bath, United Kingdom, BA1 3NG City Hospital Birmingham, United Kingdom, B18 7GH University Hospitals Bristol NHS Foundation Trust Bristol, United Kingdom, BS1 3NU University Collage London Hospitals NHS Foundation Trust London, United Kingdom, NW1 2PG The Royal Marsden NHS Foundation Trust London, United Kingdom, SM2 5PT The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX Clatterbridge Centre for Oncology NHS Foundation Trust Merseyside, United Kingdom, CH63 4JY Mount Vernon Cancer Centre (East and North Herts NHS Trust) Middlesex, United Kingdom, HA6 2RN Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust) Newcastle-upon-Tyne And Wear, United Kingdom, NE7 7DN Oxford Radcliffe Hospitals NHS Trust Oxford, United Kingdom, OX3 9DU Less <<
NCT02331498 Glioblastoma Multiforme PHASE1|PHASE2 RECRUITING 2025-08-30 Centre Antoine Lacassagne, Nic... More >>e, Cedex 2, 06189, France Less <<
NCT01759303 Osteosarcoma ... More >>Metastatic Osteosarcoma Less << Phase 2 Terminated(low accrual) - United States, California ... More >> City of Hope Duarte, California, United States, 91010 United States, Massachusetts Massachusetts General Hospital/Dana Farber Cancer Institute Boston, Massachusetts, United States, 02114 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03149120 Soft Tissue Sarcomas Phase 2 Withdrawn(No patient enrolled ... More >>as new similar study will be in system within 3 months) Less << June 2022 United States, New York ... More >> New York University School of Medicine New York, New York, United States, 10016 Less <<
NCT01600573 Ovarian Cancer Phase 1 Phase 2 Unknown March 2017 Germany ... More >> Charité Campus Virchow-Klinikum Recruiting Berlin, Germany, 13353 Contact: Jalid Sehouli, Prof. Dr.    +49 (0) 30 450 ext 564002    jalid.sehouli@charite.de    Contact: Radoslav Chekerov, Dr.    +49 (0) 30/450 ext 664399    radoslav.chekerov@charite.de    Principal Investigator: Jalid Sehouli, Prof. Dr.          Sub-Investigator: Radoslav Chekerov, Dr. Less <<
NCT01743482 Germ Cell Tumors|Measurable Di... More >>sease Less << PHASE2 COMPLETED 2016-07-27 Fondazione IRCCS Istituto Nazi... More >>onale dei Tumori, Milano, Mi, 20133, Italy Less <<
NCT02575066 Sarcoma Soft ... More >>Tissue Sarcomas Less << Phase 2 Recruiting April 2021 Netherlands ... More >> Antoni van Leeuwenhoek Recruiting Amsterdam, Netherlands, 1066CX Contact: Rick Haas, MD, PhD    +31 20 512 9111    r.haas@nki.nl    Contact: Neeltje Steeghs, MD, PhD    +31 20 512 9111    n.steeghs@nki.nl    Leids Universitair Medisch Centrum Not yet recruiting Leiden, Netherlands, 2333 ZA Contact: A.J. Verschoor, MD    +31 71 526 9111    a.j.verschoor@lumc.nl    Principal Investigator: A.J. Verschoor, MD          United Kingdom Royal Marsden Hospital Recruiting London, United Kingdom, SW3 6JJ Contact: Aisha Miah, MRCP, FRCR, PhD    +31 44 20 7808 2591    aisha.miah@rmh.nhs.uk    Principal Investigator: Aisha Miah, MRCP, FRCR, PhDMRCP, FRCR, PhD Less <<
NCT02193152 Carcinoma, Non-Small Cell Lung... More >>|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer Less << PHASE2 TERMINATED 2019-12-24 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT02303028 Solid Tumors ... More >>Central Nervous System Tumors Less << Phase 1 Phase 2 Recruiting December 2018 Canada, Alberta ... More >> Alberta Children's Hospital Recruiting Calgary, Alberta, Canada Contact: Pina Giuliano          Principal Investigator: Victor Lewis          Canada, British Columbia BC Children's Hospital Recruiting Vancouver, British Columbia, Canada Contact: Stephanie Badour          Contact: Jessica Davis          Principal Investigator: Rebecca Deyell          Canada, Manitoba CancerCare Manitoba Recruiting Winnipeg, Manitoba, Canada Contact: Rebekah Hiebert          Contact: Kathy Hjalmarsson          Principal Investigator: John Doyle          Canada, Nova Scotia IWK Health Centre Recruiting Halifax, Nova Scotia, Canada Contact: Lynn Russell          Principal Investigator: Jason Berman          Canada, Ontario Children's Hospital of Eastern Ontario (CHEO) Recruiting Ottawa, Ontario, Canada Contact: Isabelle LaForest          Principal Investigator: Donna Johnston          The Hospital for Sick Children Recruiting Toronto, Ontario, Canada Contact: Gina Lee          Principal Investigator: Daniel Morgenstern          Canada, Quebec CHU St. Justine Hopital Recruiting Montreal, Quebec, Canada Contact: Dominique Lafreniere          Principal Investigator: Monia Marzouki Less <<
NCT01521715 Locally Advanced and/or Metast... More >>atic Renal Cell Carcinoma|Carcinoma, Renal Cell|Clear-cell Metastatic Renal Cell Carcinoma Less << PHASE4 COMPLETED 2017-07-31 Urolog. Klinik im Waldkrankenh... More >>aus St. Marien, Friedrich-Alexander-Universit?t, Erlangen, 91054, Germany|Universit?tsklinikum Essen, Klinik f. Urologie, Essen, 45122, Germany|Med. Klinik II, Johann-Wolfgang-Goethe-Universit?t, Frankfurt, 60590, Germany|Medizinisches Versorgungszentrum (MVZ) Osthessen GmbH, Fulda, 36043, Germany|Universit?tsmedizin Greifswald, Greifswald, 17475, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Ludwig-Maximilians-Universit?t (LMU) München, Klinikum Grosshadern, München, 81377, Germany|Universit?tsklinikum Münster, Münster, 48149, Germany Less <<
NCT01545817 Carcinoma, Renal Cell Phase 2 Terminated(Due to changes in t... More >>he RCC treatment landscape, info gained is no longer clinically relevant to patients. Data collected is deemed sufficient to meet objectives.) Less << - Australia, Australian Capital ... More >>Territory Novartis Investigative Site Garran, Australian Capital Territory, Australia, 2606 Australia, New South Wales Novartis Investigative Site Kogarah, New South Wales, Australia, 2217 Australia, Queensland Novartis Investigative Site Auchenflower, Queensland, Australia, 4066 Novartis Investigative Site Southport, Queensland, Australia, 4215 Australia, South Australia Novartis Investigative Site Elizabeth Vale, South Australia, Australia, 5112 Novartis Investigative Site Kurralta Park, South Australia, Australia, 5037 Novartis Investigative Site Woodville, South Australia, Australia, 5011 Australia, Victoria Novartis Investigative Site Footscray, Victoria, Australia, 3011 Novartis Investigative Site Frankston, Victoria, Australia, 3199 Australia, Western Australia Novartis Investigative Site Nedlands, Western Australia, Australia, 6009 Novartis Investigative Site Perth, Western Australia, Australia, 6001 Korea, Republic of Novartis Investigative Site Gyeonggi-do, Korea, Republic of, 410-769 Novartis Investigative Site Seoul, Korea, Republic of, 110-744 Novartis Investigative Site Seoul, Korea, Republic of, 135-710 Novartis Investigative Site Seoul, Korea, Republic of, 138-736 Less <<
NCT02324803 Self Efficacy ... More >> Adverse Drug Event Carcinoma, Renal Cell Less << Phase 2 Unknown December 2015 China, Guangdong ... More >> The First Affiliated Hospital of Guangzhou Medical University Recruiting Guangzhou, Guangdong, China, 510120 Contact: Mian Xie Less <<
NCT02979899 Advanced Angiosarcoma Phase 3 Recruiting December 2019 -
NCT01642017 Metastatic Cancer (Different S... More >>olid Tumour Types) Less << PHASE1 TERMINATED 2025-03-18 H?pital Saint André, Bordeaux,... More >> 33075, France|Centre Fran?ois BACLESSE, Caen, 14076, France|Centre Léon BERARD, Lyon, 69008, France|Institut Claudius REGAUD, Toulouse, 31052, France Less <<
NCT01361334 Acute Myeloid Leukemia PHASE2 COMPLETED 2025-03-16 Unviersity Hospital of Münster... More >> (UKM), Münster, 48149, Germany Less <<
NCT01577784 Metastatic Renal Cell Carcinom... More >>a Less << PHASE2 UNKNOWN 2025-10-15 Hospital Universitario Central... More >> de Asturias, Oviedo, Asturias, 33006, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Baleares, 07010, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, 08907, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, 08208, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital General Universitario Gregorio Mara?ón, Madrid, 28009, Spain|Hospital 12 de Octubre, Madrid, 28026, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain Less <<
NCT02138526 Cancer Phase 1 Recruiting May 2018 Netherlands ... More >> RadboudUMC Recruiting Nijmegen, Gelderland, Netherlands, 6500 HB Less <<
NCT02776644 - Completed - -
NCT02551718 Acute Leukemia of Ambiguous Li... More >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia Less << Not Applicable Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker    206-616-1589    pbecker@u.washington.edu    Principal Investigator: Pamela S. Becker Less <<
NCT02795819 Renal Cell Carcinoma ... More >> Soft Tissue Sarcoma Metastatic Disease Less << Phase 1 Active, not recruiting June 30, 2025 United States, Virginia ... More >> Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less <<
NCT00610012 - Active, not recruiting August 2020 Germany ... More >> iOMEDICO Freiburg, Germany Less <<
NCT03419572 - Recruiting January 5, 2021 -
NCT01758575 - Terminated - Netherlands ... More >> VU University Medical Center Amsterdam, Netherlands, 1081HV Less <<
NCT03387514 Renal Cell Carcinoma Phase 2 Recruiting January 15, 2022 United States, Wisconsin ... More >> University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 53705 Contact: Cancer Connect    800-622-8922    cancerconnect@uwcarbone.wisc.edu Less <<
NCT02645149 Melanoma Phase 4 Not yet recruiting August 2021 Australia, New South Wales ... More >> Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Maria Gonzalez    612 9911 7200    maria.gonzalez@melanoma.org.au    Principal Investigator: John Thompson          Westmead Hospital Westmead, New South Wales, Australia, 2145 Melanoma Institute Australia Not yet recruiting Wollstonecraft, New South Wales, Australia, 2065 Contact: Maria Gonzalez    +612 9911 7200    maria.gonzalez@melanoma.org.au    Contact: Alex Menzies    +612 9911 7200    info@melanoma.org.au    Sub-Investigator: Georgina Long          Principal Investigator: Alex Menzies Less <<
NCT02788201 Urothelial Carcinoma ... More >> Bladder Cancer Urinary Bladder Neoplasms Less << Phase 2 Recruiting July 1, 2020 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT03413176 - Completed - France ... More >> AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM. Paris, France, 75013 Less <<
NCT02747173 - Terminated - Spain ... More >> Hospital Universitario central de Asturias Oviedo, Asturias, Spain, 33011 Hospital de Donostia San Sebastián, Guipuzcoa, Spain, 20080 Complejo Hospitalario Univ de Santiago de Compostela Santiago de Compostela, La Coruña, Spain, 15706 Hospital de Navarra Pamplona, Navarra, Spain, 31008 Complejo Hospitalario Univ de Vigo Vigo, Pontevedra, Spain, 36204 Consorcio Hospitalario Parc Tauli Barcelona, Spain, 08208 Complejo Hospitalario de León Leon, Spain, 24071 Hospital Univ Lucus Augusti Lugo, Spain, 27003 Complejo Hospitalario de Ourense Ourense, Spain, 32005 Instituto Valenciano de Oncologia Valencia, Spain, 46009 Hospital Universitario La Fe Valencia, Spain, 46026 Hospital Miguel Servet Zaragoza, Spain, 50009 Less <<
NCT01700699 - Unknown October 2013 Italy ... More >> Department of Medicine and Surgery, Univeristy of Salerno Recruiting Baronissi, Salerno, Italy, 84081 Contact: Mario Vitale, MD    +39 089672539    mavitale@unisa.it    Principal Investigator: Mario Vitale, MD Less <<
NCT01636908 Cancer Advanc... More >>ed Solid Tumors Less << Not Applicable Active, not recruiting - Netherlands ... More >> VUMedical Center Amsterdam, Netherlands, 1081 HV Less <<
NCT02228954 - Active, not recruiting December 2019 Netherlands ... More >> VU University Medical Center Amsterdam, Netherlands University Medical Center Groningen Groningen, Netherlands Radboudumc Nijmegen, Netherlands, 6525GA Less <<
NCT02086695 - Completed - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Canada, Manitoba St. Boniface General Hospital Winnipeg, Manitoba, Canada, R2H 2A6 Less <<
NCT02009449 Melanoma Pros... More >>tate Cancer Ovarian Cancer Renal Cell Carcinoma Colorectal Carcinoma Pancreatic Carcinoma Non-small Cell Lung Carcinoma Solid Tumors Breast Cancer Less << Phase 1 Active, not recruiting March 2020 United States, California ... More >> UCLA Medical Hematology & Oncology Los Angeles, California, United States, 90024 UCSF San Francisco, California, United States United States, Colorado Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists & Research Institute Sarasota, Florida, United States, 34232 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Oklahoma Stephenson Cancer Center at Oklahoma University TSET Phase 1 Program Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 South Texas Accelerated Research Therapeutics San Antonio, Texas, United States, 78229 Less <<
NCT02044354 Metastatic Castration-resistan... More >>t Prostate Cancer Less << Phase 3 Active, not recruiting April 2018 France ... More >> Gustave Roussy Villejuif, Val de Marne, France, 94805 Less <<
NCT01793636 Metastatic Clear Cell Renal Ca... More >>rcinoma Less << Phase 2 Terminated(Inferior efficacy o... More >>f study drug in renal indication.) Less << November 2015 United Kingdom ... More >> Royal Bournemouth Hospital Bournemouth, United Kingdom, BH7 7DW Royal Sussex County Hospital Brighton, United Kingdom, BN2 5BE University Hospitals Coventry & Warwickshire NHS Trust Coventry, United Kingdom, CV2 2DX Beatson West of Scotland Cancer Center Glasgow, United Kingdom, G12 0YN St. James' Hospital Leeds, United Kingdom, LS9 7TF Barts Health NHS Trust London, United Kingdom, EC1A 6BE Royal Free London Hospital London, United Kingdom, NW3 2QG Southampton General Hospital Southampton, United Kingdom, SO16 6YD Southend University Hospital NHS Foundation Trust Westcliff-On-Sea, United Kingdom, SS0 0RY Less <<
NCT01755195 Refractory Soft Tissue Sarcoma... More >>s Less << Phase 2 Active, not recruiting March 31, 2019 United States, California ... More >> University of California at Davis Health System Sacramento, California, United States, 95816 City of Hope Medical Group South Pasadena, California, United States, 91030 Stanford University Stanford, California, United States, 94305-5584 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT02599779 Stage IV Renal Cell Cancer AJC... More >>C V7 Less << Phase 2 Recruiting March 2021 Canada, Alberta ... More >> Tom Baker Cancer Centre Recruiting Calgary, Alberta, Canada, T2N 4N2 Contact: Richard Lee-Ying, MD       richard.lee-ying@albertahealthservices.ca    Principal Investigator: Richard Lee-Ying, MD          Canada, Ontario Sunnybrook Health Sciences Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Georg A. Bjarnason, MD    416-480-5847    georg.bjarnason@sunnybrook.ca    Contact: Nesan Bandali, RN    416-480-5000 ext 82139    nesan.bandali@sunnybrook.ca    Principal Investigator: Georg A. Bjarnason, MD          Princess Margaret Hospital Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Aaron Hansen, MD    416-946-4501    aaron.hansen@uhn.ca    Principal Investigator: Aaron Hansen, MD Less <<
NCT01620970 Transitional Cell Carcinoma of... More >> Bladder Less << Phase 2 Unknown October 2013 Italy ... More >> Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy, 20133 Less <<
NCT00782275 - Completed - -
NCT03359018 Progression-free Survival ... More >> Overall Survival Clinical Benefit Rate Toxicity Less << Phase 2 Active, not recruiting March 1, 2020 China ... More >> Musculoskeletal Tumor Center of Peking University People's Hospital Beijing, China, 100044 Peking University Shougang Hospital Beijing, China, 100144 Less <<
NCT01900743 Sarcoma Phase 2 Active, not recruiting March 31, 2019 Austria ... More >> Medizinische Universität Graz Graz, Austria, 8036 Universitätsklinik für Innere Medizin I Innsbruck, Austria, 6020 LKH Klagenfurt, Austria Krankenhaus der Barmherzigen Schwestern Linz Linz, Austria, 4010 AKH-Wien Wien, Austria, 1090 France Hôpital St Jacques Besancon, France, 25000 Institut Bergonié Bordeaux, France, 33076 Centre François Baclesse Caen, France, 14076 Centre GF Leclercq Dijon, France, 21079 Centre Oscar Lambret Lille, France, 59020 Centre Léon Bérard Lyon, France, 69373 Institut Paoli Calmettes Marseille, France, 13273 Hôpital de La Timone Marseille, France, 13354 Centre René Gauducheau Nantes, France, 44805 Centre Antoine Lacassagne Nice, France, 06189 Institut Curie Paris, France, 75005 Hôpital Saint Louis Paris, France, 75010 Hôpital Cochin Paris, France, 75014 Centre Eugène Marquis Rennes, France, 35042 Centre Henri Becquerel Rouen, France, 76038 Institut Curie - Hôpital René Huguenin Saint Cloud, France, 92210 Institut de Cancérologie Lucien Neuwirth (ICL) St Priest En Jarez, France, 42270 Institut Claudius Regaud Toulouse, France, 32052 Centre Alexis Vautrin Vandoeuvre Les Nancy, France, 54519 Institut Gustave Roussy Villejuif, France, 94800 Less <<
NCT02086734 - Completed - Germany ... More >> Urologische Klinik und Poliklinik der Universität München München, Bavaria, Germany, 81377 Less <<
NCT03456401 Renal Cancer Cell Phase 2 Terminated(availability of new... More >> and more promising therapeutic agents than expected in the experimentation in question) Less << - Italy ... More >> Istituto Tumori Milan, Mi, Italy, 20156 Less <<
NCT02156310 - Completed - Australia, South Australia ... More >> Department of Clinical Pharmacology Adelaide, South Australia, Australia, 5042 Less <<
NCT00782275 Renal Cell Carcinoma ... More >> Kidney Cancer Less << Phase 2 Completed - United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Tennessee Vanderbilt Univeristy Medical Center Nashville, Tennessee, United States, 37232 Less <<
NCT01265810 Oral Complaints ... More >> Renal Cell Carcinoma Hepatocellular Carcinoma Gastrointestinal Stromal Tumors Less << Phase 3 Completed - Netherlands ... More >> The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Amsterdam, Netherlands, 1066 CX Leiden University Medical Centre (LUMC) Leiden, Netherlands, 2300 RC Less <<
NCT02751827 - Recruiting February 2019 France ... More >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Antoine ITALIANO, MD,PhD          Principal Investigator: Antoine ITALIANO, MD,PhD          Centre Léon Bérard Not yet recruiting Lyon Cedex 08, France, 69373 Contact: Jean-Yves BLAY, MD, PhD          Principal Investigator: Jean-Yves BLAY, MD, PhD Less <<
NCT01391962 Sarcoma, Alveolar Soft Part Phase 2 Recruiting December 15, 2019 United States, California ... More >> Santa Monica Oncology Center Recruiting Santa Monica, California, United States, 90403 Contact: Shivaani Kummar, M.D.    301-435-5402    kummars@mail.nih.gov    United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    (888) NCI-1937       United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030-4096 Canada, Ontario Princess Margaret Cancer Center Recruiting Toronto, Ontario, Canada, M5G2M9 Less <<
NCT02789137 - Recruiting October 30, 2018 Spain ... More >> Hospital Arquitecto Marcide de Ferrol Recruiting Ferrol, A Coruña, Spain, 15405 Hospital Asil de Granollers Recruiting Granollers, Barcelona, Spain, 08402 Hospital Parc Taulí Recruiting Sabadell, Barcelona, Spain, 08208 Hospital Galdakano Recruiting Usansolo, Bizkaia, Spain, 48960 Complejo Hospitalario la Mancha Centro Recruiting Alcazar de San Juan, Ciudad REAL, Spain, 13600 Hospital Universitari Son Espases Recruiting Palma, Mallorca, Spain, 07120 H. Universitario Infanta Cristina Recruiting Badajoz, Spain, 06006 Hospital Vall de Hebrón Recruiting Barcelona, Spain, 08035 Hospital Universitario Ciudad Real Recruiting Ciudad Real, Spain, 13005 H. Reina Sofía de Cordoba Recruiting Córdoba, Spain, 14004 Hospital de Cabueñes Not yet recruiting Gijón, Spain, 33394 ICO Girona (Hospital Dr.Josep Trueta) Recruiting Girona, Spain, 17007 Hospital Universitario de Guadalajara Not yet recruiting Guadalajara, Spain, 19002 Complejo Hospitalario de Jaén Recruiting Jaén, Spain, 23007 Complejo Hospitalario de León Recruiting León, Spain, 24071 Complejo Hospitalario Ourense. Hospital Santa María Nai Recruiting Ourense, Spain, 32005 Hospital General de Asturias Not yet recruiting Oviedo, Spain, 33011 Complejo Hospitalario de Navarra Recruiting Pamplona, Spain, 31008 Hospital Universitario Canarias Not yet recruiting Santa Cruz de Tenerife, Spain, 38320 Hospital de Sant Pau i Santa Tecla Recruiting Tarragona, Spain, 43003 Hospital Virgen de la Salud Recruiting Toledo, Spain, 45071 Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain, 46011 H Clínico Zaragoza Recruiting Zaragoza, Spain, 50009 Less <<
NCT01224288 Renal Cell Carcinoma Phase 3 Active, not recruiting January 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02048371 Liposarcoma O... More >>steogenic Sarcoma Ewing/Ewing-like Sarcoma Rhabdomyosarcoma Less << Phase 2 Recruiting December 2020 United States, California ... More >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Torie Fechner    626-256-4673    tfechner@coh.org    Principal Investigator: Warren Chow, MD          Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Magnolia Manzano    323-361-8156    mmanzano@chla.usc.edu    Sarcoma Oncology Research Center Recruiting Santa Monica, California, United States, 90403 Contact: Victoria Chua    310-552-9999    vchua@sarcomaoncology.com    Principal Investigator: Sant Chawla, MD          Stanford University Recruiting Stanford, California, United States, 94305 Contact: Maria Ahern    650-725-6413    mahern@stanford.edu    Principal Investigator: Kristen Ganjoo, MD          United States, Florida Mayo Clinic - Florida Recruiting Jacksonville, Florida, United States, 32224 Contact: Steven Attia, DO    904-953-7292    Attia.Steven@mayo.edu    Principal Investigator: Steven Attia, DO          H. Lee Moffitt Terminated Tampa, Florida, United States, 33612 United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Rasima Cehic    312-695-2082    rasima.cehic@northwestern.edu    Principal Investigator: Mark Agulnik, MD          United States, Indiana Indiana University Recruiting Indianapolis, Indiana, United States, 46202 Contact: Michele Niland    317-278-0778    mniland@iupui.edu    Principal Investigator: Daniel Rushing, MD          United States, Massachusetts Dana Farber/Partners Cancer Care Terminated Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic - Minnesota Recruiting Rochester, Minnesota, United States, 55905 Contact: Elizabeth Smith    507-293-3817    Smith.Elizabeth6@mayo.edu    Principal Investigator: Scott Okuno, MD          United States, North Carolina Carolinas Healthcare System Recruiting Charlotte, North Carolina, United States, 28203 Contact: Michelle Treadwell    980-442-2332    Michelle.Treadwell@carolinashealthcare.org    Principal Investigator: Michael Livingston, MD          Duke University Recruiting Durham, North Carolina, United States, 27705 Contact: Colleen Piechocki    919-681-1883    colleen.piechocki@duke.edu    Principal Investigator: Richard Riedel, MD          United States, Ohio Ohio State University Recruiting Columbus, Ohio, United States, 43202 Contact: Comprehensive Cancer Center    800-293-5066    Jamesline@osumc.edu    Principal Investigator: David Liebner, MD          United States, Oregon Oregon Health and Science University Recruiting Portland, Oregon, United States, 97239 Contact: David Boody-Alter    503-418-9655    boodyalt@ohsu.edu    Principal Investigator: Lara Davis, MD          United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37232 Contact: Melissa Sindler    615-875-0060    melissa.m.sindler@vanderbilt.edu    Principal Investigator: Vicky Keedy, MD          United States, Utah Huntsman Cancer Institute Recruiting Salt Lake City, Utah, United States, 84112 Contact: Justin Parker    801-587-4702    justin.parker@hci.utah.edu    Principal Investigator: Jennifer Wright, MD          United States, Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States, 98109 Contact: Roxanne Moore    206-288-6425    romoore@seattlecca.org    Principal Investigator: Elizabeth Loggers, MD, PhD Less <<
NCT02338570 Renal Cell Carcinoma Phase 4 Terminated(Stopped on November... More >> 16th 2016, because of recruitment failure.) Less << - Italy ... More >> Spedali Civili Brescia, Italy Ospedale A Perrino Brindisi, Italy Istituto Europeo di Oncologia Milano, Italy Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale Napoli, Italy AOU Maggiore della Carità Novara, Italy Casa di Cura La Maddalena Palermo, Italy Unicampus Biomedico Roma, Italy AOU San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy Less <<
NCT02029001 Malignant Solid Neoplasms Phase 2 Recruiting October 2022 France ... More >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Antoine ITALIANO    +335 56 33 33 33    a.italiano@bordeaux.unicancer.fr    Principal Investigator: Antoine ITALIANO          Sub-Investigator: Delphine GARBAY          Sub-Investigator: Maud TOULMONDE          Sub-Investigator: Sophie COUSIN          Sub-Investigator: Sylvestre LE MOULEC          Sub-Investigator: Mathilde CABART          Sub-Investigator: Guilhem ROUBAUD          Centre Jean Perrin Not yet recruiting Clermont-Ferrand, France, 63011 Contact: Xavier DURANDO    04 73 27 81 31    xavier.durando@cjp.fr    Principal Investigator: Xavier DURANDO          Sub-Investigator: Pierre DALLOZ          Sub-Investigator: Anne-Françoise DILLIES-LEGRAIN          Sub-Investigator: Pascale DUBRAY-LONGERAS          Sub-Investigator: Hakim MAHAMMEDI          Sub-Investigator: Marie-Ange MOURET-REYNIER          Sub-Investigator: Isabelle VAN PRAAGH DOREAU          Institut Daniel Hollard Not yet recruiting Grenoble, France, 38028 Contact: Cécile LEYRONNAS    04 76 70 73 33    c.leyronnas@ghm-grenoble.fr    Principal Investigator: Cécile LEYRONNAS, MD          Sub-Investigator: Claire GARNIER-TIXIDRE, MD          Sub-Investigator: Laurence LANCRY-LECOMTE, MD          Sub-Investigator: Jérôme LONG, MD          Sub-Investigator: Christine REBISCHUNG, MD          Centre Leon Berard Recruiting Lyon, France, 69373 Contact: Jean-Yves BLAY    +33478785126    jean-yves.blay@lyon.unicancer.fr    Principal Investigator: Jean-Yves BLAY, MD          Sub-Investigator: Virginie AVRILLON          Sub-Investigator: Thomas BACHELOT          Sub-Investigator: Christophe BERGERON          Sub-Investigator: Pierre BIRON          Sub-Investigator: Helen BOYLE          Sub-Investigator: Philippe CASSIER          Sub-Investigator: Patrick COMBEMALE          Sub-Investigator: Maria CHELGHOUM          Sub-Investigator: Françoise DESSEIGNE          Sub-Investigator: Cécile FAURE-CONTER          Sub-Investigator: Jérome FAYETTE          Sub-Investigator: Aude FLECHON          Sub-Investigator: Christelle DE LA FOUCHARDIERE          Sub-Investigator: Didier FRAPPAZ          Sub-Investigator: Pierre GUIBERT          Sub-Investigator: Pierre-Etienne HEUDEL          Sub-Investigator: Eve-Marie NEIDHARDT          Sub-Investigator: Maurice PEROL          Sub-Investigator: Isabelle RAY-COQUARD          Sub-Investigator: Paul REBATTU          Sub-Investigator: Pierre SAINTIGNY          Sub-Investigator: Catherine TERRET          Sub-Investigator: Olivier TREDAN          Sub-Investigator: Olivia BALLY          Sub-Investigator: Stéphane DEPIL          Sub-Investigator: Olfa DERBEL          Sub-Investigator: Nathalie MARQUES          Sub-Investigator: Philippe TOUSSAINT          Sub-Investigator: Mehdi BRAHMI          Sub-Investigator: Matthieu SARABI          Sub-Investigator: Alice BONNEVILLE-LEVARD          Sub-Investigator: Nadège CORRADINI          Sub-Investigator: Louis DOUBLET          Sub-Investigator: Armelle DUFRESNE          Sub-Investigator: Lauriane EBERST          Sub-Investigator: Sylvie NEGRIER          Sub-Investigator: Katell MICHAUX          Sub-Investigator: Anne-Sophie MICHALLET          Sub-Investigator: Guillaume MAURICEAU          Sub-Investigator: Juliette REURE          Sub-Investigator: Pauline ROCHEFORT          Hopital Edouard Herriot Not yet recruiting Lyon, France, 69437 Contact: Julien FORESTIER, MD    +33472119738    julien.forestier@chu-lyon.fr    Principal Investigator: Julien FORESTIER          Sub-Investigator: Catherine LOMBARD BOHAS          Sub-Investigator: Thomas WALTER          Sub-Investigator: Yann MOLIN          Sub-Investigator: Noura BEN SLAMA          Institut Paoli Calmettes Recruiting Marseille, France, 13273 Contact: François BERTUCCI    +334 91 22 35 37    bertuccif@ipc.unicancer.fr    Principal Investigator: François BERTUCCI          Sub-Investigator: Jean-Marc EXTRA          Sub-Investigator: Anthony GONCALVES          Sub-Investigator: Gwenaêlle GRAVIS-MESCAM          Sub-Investigator: Anne MADROSZYK-FLANDIN          Sub-Investigator: Jean-Luc RAOUL          Sub-Investigator: Delphine PERROT          Sub-Investigator: Magali PROVENSAL          Sub-Investigator: Carole TARPIN          Sub-Investigator: Frédéric VIRET          Sub-Investigator: Louis TASSY          Sub-Investigator: Maria Antonietta CAPPIELLO          Sub-Investigator: Slimane DERMECHE          Sub-Investigator: Simon LAUNAY          Sub-Investigator: Frederique ROUSSEAU          Sub-Investigator: Nicolas MEYER          Sub-Investigator: Loïc MOUREY          Sub-Investigator: Elisabeth MOYAL          Sub-Investigator: Roxana Maria RADUT          Sub-Investigator: Henri ROCHE          Sub-Investigator: Thibaud VALENTIN          Sub-Investigator: Sarah ZAHI          Institut Curie Recruiting Paris, France, 75248 Contact: Christophe LE TOURNEAU, MD    +33144324672    Christophe.letourneau@curie.fr    Principal Investigator: Christophe LE TOURNEAU, MD          Sub-Investigator: Philippe BEUZEBOC          Sub-Investigator: François-Clément BIDARD          Sub-Investigator: Bruno BUECHER          Sub-Investigator: Paul-Henri COTTU          Sub-Investigator: Catherine DANIEL          Sub-Investigator: Véronique DIERAS          Sub-Investigator: Valérie LAURENCE          Sub-Investigator: Alain LIVARTOWSKI          Sub-Investigator: Jean-Yves PIERGA          Sub-Investigator: Marie ALT          Sub-Investigator: Delphine LOIRAT          Sub-Investigator: Marie-Paule SABLIN          Sub-Investigator: Mustapha ZOUBIR          Sub-Investigator: Francesco RICCI          Sub-Investigator: Emanuela ROMANO          Sub-Investigator: Olivier COLLARD          Centre Hospitalier Lyon Sud Recruiting Pierre-Bénite, France, 69495 Contact: Benoit YOU, MD    +33478864319    benoit.you@chu-lyon.fr    Principal Investigator: Benoit YOU, MD          Sub-Investigator: Nathalie BONNIN          Sub-Investigator: Gilles FREYER          Sub-Investigator: Salima HAMIZI          Sub-Investigator: Sophie TARTAS          Sub-Investigator: Véronique TRILLET-LENOIR          Sub-Investigator: Marion CHAUVENET          Sub-Investigator: Denis MAILLET          Sub-Investigator: Julien PERON          Sub-Investigator: Claire FALANDRY          Sub-Investigator: Olivia LE SAUX          Institut de cancérologie LUCIEN NEUWIRTH Not yet recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Olivier COLLARD, MD    04 77 91 70 34    olivier.collard@icloire.fr    Principal Investigator: Olivier COLLARD, MD          Sub-Investigator: Claire BOSACKI, MD          Sub-Investigator: Pierre FOURNEL, MD          Sub-Investigator: Aline GUILLOT, MD          Sub-Investigator: Jean-Philippe JACQUIN, MD          Sub-Investigator: Thierry MURON, MD          Sub-Investigator: Léa SABAN-ROCHE, MD          Institut Claudius Regaud Recruiting Toulouse, France, 31059 Contact: Carlos-Alberto GOMEZ-ROCA    05 31 15 51 01    Gomez-roca.carlos@iuct-oncopole.fr    Principal Investigator: Carlos-Alberto GOMEZ-ROCA          Sub-Investigator: Christine CHEVREAU          Sub-Investigator: Ewa-Anna COTTURA          Sub-Investigator: Florence DALENC          Sub-Investigator: Jean-Pierre DELORD          Sub-Investigator: Marion DESLANDRES          Sub-Investigator: Cécile GANDY          Sub-Investigator: Laurence GLADIEFF          Sub-Investigator: Eleonora MAIO D'ESPOSITO          Sub-Investigator: Nicolas MEYER          Sub-Investigator: Loïc MOUREY          Sub-Investigator: Elisabeth MOYAL          Sub-Investigator: Henri ROCHE          Sub-Investigator: Thibaud VALENTIN          Sub-Investigator: Sarah ZAHI          Sub-Investigator: Roxana Maria RADUT Less <<
NCT01649180 Renal Cell Carcinoma Phase 2 Terminated(Closed due to prolo... More >>nged enrollment timelines) Less << - United States, Nebraska ... More >> Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68106 United States, Ohio Cleveland Clinic, Taussig Cancer Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania, Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT01649180 - Terminated(Closed due to prolo... More >>nged enrollment timelines) Less << - -
NCT02071719 - Terminated October 2017 Netherlands ... More >> VU Medical Center Amsterdam, Noord Holland, Netherlands, 1081 HV Less <<
NCT02638428 Relapsed Pediatric Solid Tumor... More >> Refractory Pediatric Solid Tumor Relapsed Pediatric AML Refractory Pediatric AML Less << Phase 2 Recruiting December 2023 Korea, Republic of ... More >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Ki Woong Sung    82-2-3410-3529    kwsped@skku.edu    Principal Investigator: Ki Woong Sung Less <<
NCT02956798 Oligometastatic Renal Cell Car... More >>cinoma Less << Phase 2 Recruiting December 31, 2021 United States, Texas ... More >> University of Texas Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390 Contact: Raquibul Hannan, MD    214-645-7696    Raquibul.Hannan@UTSouthwestern.edu    Contact: Mehreen Aslam    214-648-8038    Mehreen.Aslam@UTSouthwestern.edu    Principal Investigator: Raquibul Hannan, MD, PhD Less <<
NCT03185039 Kidney Cancer Not Applicable Recruiting November 29, 2020 France ... More >> Institut Paoli Calmettes Recruiting Marseille, France, 13009 Contact: GENRE Dominique, MD    33 (0)4 91 22 37 78    drci.up@ipc.unicancer.fr    Contact: Isabelle Boquet, PhD    33 (0)4 91 22 37 78    drci.up@ipc.unicancer.fr    Principal Investigator: GRAVIS Gwénaëlle, MD Less <<
NCT00666081 Cancer Phase 1 Withdrawn(Study Cancelled befo... More >>re enrollment) Less << December 2009 -
NCT02560012 Carcinoma, Renal Cell Phase 2 Terminated(Loss of laboratory ... More >>performing molecular analysis) Less << - United States, Texas ... More >> UTHealth Memorial Hermann Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02354612 Solid Tumors Phase 1 Phase 2 Enrolling by invitation December 2021 United States, California ... More >> UCLA Santa Monica, California, United States, 90404 Less <<
NCT02700568 Carcinoma, Renal Cell ... More >> Clear Cell Renal Cell Carcinoma Less << Phase 2 Recruiting August 2018 Russian Federation ... More >> Demchenkova Marina Viktorovna Recruiting Irkutsk, Russian Federation Semenov Andrey Vladimirovich Recruiting Ivanovo, Russian Federation Mikhailova Nadezhda Vasilievna Recruiting Kazan, Russian Federation Eskerov Kurban Abdulmutalibovich Active, not recruiting Kirov, Russian Federation Zukov Ruslan Aleksandrovich Recruiting Krasnoyarsk, Russian Federation Ovchinnikova Elena Georgievna Recruiting Nizhny Novgorod, Russian Federation Guseva Irina Vasilievna Recruiting Penza, Russian Federation Vladimirova Lyubov Yur'evna Active, not recruiting Rostov-on-Don, Russian Federation Zolotoreva Tatiana Gennadievna Recruiting Samara, Russian Federation Katkov Alexey Aleksandrovich Active, not recruiting Saratov, Russian Federation Ivannikov Andrey Andreyevich Recruiting Tambov, Russian Federation Usynin Evgeny Anatolievich Recruiting Tomsk, Russian Federation Evstegneyeva Irina Vladimirovna Recruiting Tver, Russian Federation Khmelevsky Andrey Anatolievich Recruiting Ufa, Russian Federation Gurina Ludmila Ivanovna Active, not recruiting Vladivostok, Russian Federation Less <<
NCT01731158 Metastatic Renal Cell Carcinom... More >>a Less << Phase 2 Unknown May 2016 Germany ... More >> Charité Berlin Berlin, Germany University Hospital Bonn Bonn, Germany University Hospital Dresden Dresden, Germany University Hospital Düsseldorf Düsseldorf, Germany Waldkrankenhaus St. Marien Erlangen, Germany University Hospital Essen Essen, Germany University Hospital Frankfurt Frankfurt, Germany University Hospital Freiburg Freiburg, Germany University Hospital Göttingen Göttingen, Germany Oncological Practice Hannover Hannover, Germany University Hospital Hannover Hannover, Germany University Hospital Magdeburg Magdeburg, Germany University Hospital Tübingen Tübingen, Germany Less <<
NCT02184416 - Recruiting July 20, 2019 -
NCT02560012 - Terminated(Loss of laboratory ... More >>performing molecular analysis) Less << - -
NCT02049905 Metastatic, Locally Advanced o... More >>r Unresectable Soft Tissue Sarcoma Less << Phase 3 Completed - -
NCT02960906 Clear Cell Metastatic Renal Ce... More >>ll Carcinoma Less << Phase 2 Recruiting May 2020 France ... More >> Hôpital Saint André, CHU de Bordeaux Recruiting Bordeaux, France, 33075 Contact: Marine GROSS-GOUPIL, MD       marine.gross-goupil@chu-bordeaux.fr    Centre Francois Baclesse Recruiting Caen, France, 14000 Contact: Florence JOLY, MD,PHD       f.joly@baclesse.unicancer.fr    CHU Henri-Mondor Recruiting Creteil, France, 94000 Contact: Christophe TOURNIGAND, MD, PHD       christophe.tournigand@aphp.fr    CHD Vendée Not yet recruiting La Roche-sur-Yon, France, 85925 Contact: Franck PRIOU, MD       frank.priou@chd-vendee.fr    Centre OSCAR LAMBRET LILLE Recruiting Lille, France, 59000 Contact: Yaovi Messan AMELA, MD       e-amela@o-lambret.fr    Hôpital Européen Marseille Not yet recruiting Marseille, France, 13003 Contact: Philippe DALIVOUST       philippe.dalivoust@gmail.com    Institut Paoli Calmettes (IPC) Recruiting Marseille, France, 13009 Contact: Gwenaëlle GRAVIS, MD       gravisg@ipc.unicancer.fr    Centre Antoine Lacassagne Recruiting Nice, France, 06100 Contact: Delphine BORCHIELLINI, MD       Delphine.BORCHIELLINI@nice.unicancer.fr    Institut de Cancérologie du Gard - CHU Caremeau Recruiting Nîmes, France, 30029 Contact: Nadine HOUEDE, MD,PHD       HOUEDE nadine    Hôpital Pitié-Salpêtrière Withdrawn Paris, France, 75013 Institut Mutualiste Montsouris Recruiting Paris, France, 75014 Contact: Mostefa BENNAMOUN, MD       Mostefa.Bennamoun@imm.fr    Hôpital Européen Georges Pompidou Recruiting Paris, France, 75015 Contact: Yann-Alexandre VANO, MD       yann.vano@aphp.fr    Hôpital de la Croix Saint-Simon Not yet recruiting Paris, France, 75020 Contact: Jacques MEDIONI       JMedioni@hopital-dcss.org    Hôpital Cochin Recruiting Paris, France, 75679 Contact: Olivier HUILLARD, MD       olivier.huillard@aphp.fr    Centre Hospitalier Lyon Sud - Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL) Not yet recruiting Pierre Bénite, France, 69310 Contact: Denis MAILLET, MD       denis.maillet@chu-lyon.fr    Centre Eugene Marquis Recruiting Rennes, France, 35042 Contact: Brigitte LAGUERRE, MD       b.laguerre@rennes.unicancer.fr    Centre René Gauducheau ICO institut de Cancerologie de l'Ouest Not yet recruiting Saint-Herblain, France, 44805 Contact: Frédéric ROLLAND, MD       Frederic.Rolland@ico.unicancer.fr    Hôpitaux universitaires de Strasbourg Recruiting Strasbourg, France, 67000 Contact: Philippe BARTHELEMY, MD       philippe.barthelemy@chru-strasbourg.fr    Hopital Foch Not yet recruiting Suresnes, France, 92151 Contact: Philippe BEUZEBOC       beuzeboc.philippe@gmail.com    Institut Claudius Regaud Recruiting Toulouse, France, 31059 Contact: Christine CHEVREAU, MD       Chevreau.Christine@iuct-oncopole.fr    CHU Bretonneau Recruiting Tours, France, 37000 Contact: Claude LINASSIER, MD       claude.linassier@univ-tours.fr    Institut Gustave Roussy Not yet recruiting Villejuif, France, 94805 Contact: Laurence ALBIGES, MD       Laurence.ALBIGES@gustaveroussy.fr Less <<
NCT00749320 Renal Cell Carcinoma Not Applicable Active, not recruiting February 2019 United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT02187302 Metastatic Renal Cell Carcinom... More >>a Less << Phase 2 Completed - -
NCT03379012 Metastatic Renal Cell Carcinom... More >>a Less << Phase 2 Recruiting July 30, 2019 Russian Federation ... More >> A.I. Kryzhanovsky Krasnoyarsk Cancer Center Recruiting Krasnoyarsk, Russian Federation Contact: Ruslan Zukov       kidneycancer@yandex.ru    Kidney Cancer Research Bureau Recruiting Moscow, Russian Federation Contact: Ilya Tsimafeyeu       kidneycancer@yandex.ru    RUDN University Recruiting Moscow, Russian Federation Contact: Yuliya Tishova       kidneycancer@yandex.ru    City Clinical Oncology Center Recruiting Saint Petersburg, Russian Federation Contact: Pavel Borisov       kidneycancer@yandex.ru Less <<
NCT03062410 Renal Carcinoma Metastatic ... More >> Kidney Neoplasms Renal Cancer Less << Not Applicable Recruiting February 4, 2020 France ... More >> CHU de Besançon Active, not recruiting Besançon, France, 25030 Hôpital privé Sainte Marie Recruiting Chalon-sur-Saône, France, 71100 Contact: Erika Viel, MD    0033385488989       Centre de lutte contre le cancer Georges François Leclerc Recruiting Dijon, France, 21000 Contact: Sylvain Ladoire, MD    0033380737506    sladoire@cgfl.fr    Hôpital Nord Franche-Comté Recruiting Montbéliard, France, 25200 Contact: Guillaume Mouillet, MD       mouillet.guillaume@gmail.com    Centre de lutte contre le cancer Jean Godinot Recruiting Reims, France, 51100 Contact: Jean-Christophe Eymard, MD          Groupe hospitaliser St-Vincent Recruiting Strasbourg, France, 67000 Contact: Louis-Marie Dourthe, MD       lm.dourthe@solcrr.org    Hôpitaux Universitaires de Strasbourg Recruiting Strasbourg, France, 67000 Contact: Philippe Barthelemy, MD       philippe.barthelemy@chru-strasbourg.fr    Centre de lutte contre le cancer Alexis Vautrin - Institut de Cancérologie de Lorraine Recruiting Vandœuvre-lès-Nancy, France, 54519 Contact: Lionnel Geoffrois, MD       l.geoffrois@nancy.unicancer.fr Less <<
NCT01582204 Renal Cancer Not Applicable Active, not recruiting April 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT01217931 Kidney Cancer Phase 2 Active, not recruiting January 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01594203 - Unknown May 2013 Israel ... More >> Hadassah Hebrew University Medical Center Not yet recruiting Jerusalem, Israel Contact: Marina Orevi, MD       marinaor@hadassah.org.il    Contact: Daniela Katz, MD       DanielaKatz@hadassah.org.il Less <<
NCT03275558 Recurrent Glioblastoma ... More >> Gliosarcoma Anaplastic Gliomas Less << Phase 1 Withdrawn(Study halted prior t... More >>o enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)) Less << - Hong Kong ... More >> The Hong Kong Cancer Institute Hong Kong, Hong Kong, 518031 Singapore National University Cancer Institute, Singapore, Singapore, 119074 Less <<
NCT03571438 Kidney Cancer Not Applicable Recruiting September 30, 2024 France ... More >> Grenoble Alps Hospital Recruiting Grenoble, France, 38043 Contact: Jean-Luc Descotes, PU-PH Less <<
NCT02208128 Renal Cell Carcinoma Not Applicable Unknown February 2018 Germany ... More >> Urological Department of the University Hospital Heidelberg Recruiting Heidelberg, Germany, 69120 Contact: Sascha Pahernik, PD Dr.    +49 6221 56 39689    sascha.pahernik@med.uni-heidelberg.de    Principal Investigator: Sascha Pahernik, PD Dr. Less <<
NCT02406521 Metastatic Renal Cell Carcinom... More >>a Less << Phase 1 Active, not recruiting December 2018 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT02959554 Metastatic Renal Cell Carcinom... More >>a Less << Phase 2 Active, not recruiting December 2021 Austria ... More >> Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie Wien, Austria, 1090 Germany Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie Essen, Germany, 45147 Less <<
NCT01202032 Metastatic Renal Cell Carcinom... More >>a Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed Less << Phase 1 Completed - France ... More >> Centre Léon BERARD Lyon, France, 69373 Less <<
NCT02535351 Clear-cell Metastatic Renal Ce... More >>ll Carcinoma Less << Phase 3 Terminated(low enrolment) - Italy ... More >> Fondazione IRCCS Istituto Nazionale Tumori Milan, Mi, Italy, 20133 Less <<
NCT03519542 - Active, not recruiting June 2018 Spain ... More >> Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, A Coruña, Spain, 15706 Hospital Universitario central de Asturias Oviedo, Asturias, Spain, 33011 Hospital Marqués de Valdecilla Santander, Cantabria, Spain, 39008 Hospital Universitarios de Burgos Burgos, Spain, 09006 Hospital Universiario de León León, Spain, 24080 Hospital Gregorio Marañón Madrid, Spain, 28007 Hospital Universitario Ramón y Cajal Madrid, Spain, 28024 Hospital Clínico (Madrid) Madrid, Spain, 28040 Hospital 12 de Octubre Madrid, Spain, 28041 Hospital Universitario La Paz Madrid, Spain Hospital Universitario Carlos Haya Málaga, Spain, 29010 Hospital Clínico Lozano Blesa Zaragoza, Spain, 50009 Less <<
NCT00060151 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, North Carolina ... More >> Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 United States, Ohio Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 Less <<
NCT01716546 Gastric Cancer PHASE1|PHASE2 TERMINATED 2025-01-15 "IASO" General Hospital of Ath... More >>ens, Athens, Greece|401 Military Hospital of Athens, Athens, Greece|Air Forces Military Hospital of Athens, Athens, Greece|"Ag.Georgios" General Hospital of Chania, Chania, Greece|University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece, Heraklion, Greece|State General Hospital of Larissa, Larissa, Greece|"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece|"Theagenion" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, Greece|Diabalkaniko General Hospital of Thessaloniki, Thessaloniki, Greece Less <<
NCT01381614 - Completed - -
NCT01514448 Metastatic Renal Cell Carcinom... More >>a (mRCC) Less << Phase 4 Completed - Germany ... More >> Novartis Investigative Site Chemnitz, Germany, 09130 Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Hannover, Germany, 30559 Novartis Investigative Site Hof, Germany, 95028 Novartis Investigative Site Kassel, Germany, 34125 Novartis Investigative Site Langen, Germany, 63225 Novartis Investigative Site Leipzig, Germany, 04357 Novartis Investigative Site Magdeburg, Germany, 39120 Novartis Investigative Site Muenster, Germany, 48149 Novartis Investigative Site Ravensburg, Germany, 88214 Novartis Investigative Site Velbert, Germany, 42551 Novartis Investigative Site Wiesbaden, Germany, 65191 Novartis Investigative Site Wolfsburg, Germany, 38440 Less <<
NCT03260894 Renal Cell Carcinoma (RCC) Phase 3 Active, not recruiting June 2020 -
NCT01381601 - Completed - -
NCT00158782 Carcinoma, Renal Cell Phase 1 Completed - United States, North Carolina ... More >> GSK Investigational Site Durham, North Carolina, United States, 27705 Netherlands GSK Investigational Site Rotterdam, Netherlands, 3075 EA Less <<
NCT01664182 Stage III Renal Cell Cancer AJ... More >>CC v7 Stage IV Renal Cell Cancer AJCC v7 Less << Phase 2 Active, not recruiting - United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 City of Hope South Pasadena South Pasadena, California, United States, 91030 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Metro Minnesota Community Oncology Research Consortium Saint Louis Park, Minnesota, United States, 55416 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Virginia VCU Massey Cancer Center at Hanover Medical Park Mechanicsville, Virginia, United States, 23116 Less <<
NCT01408004 Clear Cell Renal Carcinoma Phase 2 Completed - Netherlands ... More >> St. Franciscus Gasthuis Rotterdam, Zuid-Holland, Netherlands Medisch Centrum Alkmaar Alkmaar, Netherlands Acedemisch Medisch Centrum Amsterdam Amsterdam, Netherlands NKI-AVL Amsterdam, Netherlands Amphia ziekenhuis Breda Breda, Netherlands Haga Ziekenhuis Den Haag, Netherlands Maxima Medisch Centrum Eindhoven, Netherlands UMC Groningen Groningen, Netherlands Atrium Medisch Centrum Heerlen Heerlen, Netherlands Medische Centrum Leeuwarden Leeuwarden, Netherlands Acedemisch ziekenhuis Maastricht Maastricht, Netherlands St. Antonius ziekenhuis Nieuwegein, Netherlands Erasmus Medisch Centrum Rotterdam, Netherlands Orbis Medisch Centrum Sittard-Geleen, Netherlands St. Elisabeth ziekenhuis Tilburg, Netherlands UMC Utrecht Utrecht, Netherlands, 3508 GA Isala klinieken Zwolle, Netherlands Less <<
NCT01208064 Lung Cancer Phase 2 Phase 3 Terminated(based on IDMC decis... More >>ion) Less << - Belgium ... More >> Universitair Ziekenhuis Gent Gent, Belgium Centre Hospitalier Regional De La Citadelle Liege, Belgium Clinique et Maternité Sainte Elisabeth Namur, Belgium Egypt National Cancer Institute Cairo, Egypt France Centre Georges-Francois-Leclerc Dijon, France Assistance Publique - Hôpitaux de Marseille - Assistance Publique - Hôpitaux de Marseille - Hopital Nord Marseille, France Germany Klinik Loewenstein Loewenstein, Germany UniversitaetsMedizin Mannheim Mannheim, Germany Greece University General Hospital Heraklion Heraklion, Greece Netherlands The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis Amsterdam, Netherlands Amphia Ziekenhuis Breda, Netherlands Isala Klinieken Zwolle, Netherlands Slovenia University Clinic Golnik Golnik, Slovenia United Kingdom Royal Marsden - Surrey Sutton, England, United Kingdom, SM2 5PT Western General Hospital Edinburgh, United Kingdom Guy's and St Thomas' NHS London, United Kingdom Royal Marsden Hospital London, United Kingdom Christie NHS Foundation Trust Manchester, United Kingdom Nottingham University Hospitals NHS Trust Nottingham, United Kingdom Weston Park Hospital Sheffield, United Kingdom King's Mill Hospital Sutton-in-Ashfield, United Kingdom Royal Marsden Hospital Sutton, United Kingdom Less <<
NCT00347919 Neoplasms, Breast Phase 2 Completed - -
NCT00733304 Macular Degeneration PHASE2 COMPLETED 2009-09-09 GSK Investigational Site, Beve... More >>rly Hills, California, 90211, United States|GSK Investigational Site, Sacramento, California, 95841, United States|GSK Investigational Site, Winter Haven, Florida, 33880, United States|GSK Investigational Site, Indianapolis, Indiana, 46280, United States|GSK Investigational Site, Boston, Massachusetts, 02111, United States|GSK Investigational Site, Ann Arbor, Michigan, 48105, United States|GSK Investigational Site, Grand Rapids, Michigan, 49525, United States|GSK Investigational Site, Salt Lake City, Utah, 84132, United States|GSK Investigational Site, Sydney, New South Wales, 2145, Australia|GSK Investigational Site, Sydney, New South Wales, 2150, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Perth, Western Australia, 6009, Australia|GSK Investigational Site, Milano, Lombardia, 20132, Italy|GSK Investigational Site, Milano, Lombardia, 20157, Italy|GSK Investigational Site, Torino, Piemonte, 10122, Italy|GSK Investigational Site, Firenze, Toscana, 50134, Italy|GSK Investigational Site, Padova, Veneto, 35128, Italy Less <<
NCT00347919 - Completed - -
NCT01861951 Soft Tissue Sarcoma Phase 2 Completed - Belgium ... More >> University Hospitals Leuven, Leuven Cancer Institute, Dept. of General Medical Oncology Leuven, Flemish Brabant, Belgium, 3000 Germany Heidelberg University Hospital, Department of Internal Medicine, Hematology, Oncology and Rheumatology Heidelberg, Baden-Wuerttemberg, Germany, 69120 University Medical Centre Mannheim, Surgical oncology Mannheim, Baden-Wuerttemberg, Germany, 68167 Medical University Tuebingen, Center for Soft Tissue Sarcoma, GIST and Bone Tumors Tuebingen, Baden-Wuerttemberg, Germany, 72076 LMU University hospital Munich Grosshadern, Medical Dept. III Munich, Bavaria, Germany, 81377 Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hanover, Lower Saxony, Germany, 30625 University Hospital RWTH Aachen, Medical Dept. IV Aachen, North Rhine-Westphalia, Germany, 52074 University Hospital Cologne Cologne, North Rhine-Westphalia, Germany, 50937 University Hospital Essen, West-German Tumor Center Essen, North Rhine-Westphalia, Germany, 45122 University Hospital Carl Gustav Carus, Internal Medicine Dept. I Dresden, Saxony, Germany, 01307 Charité Hospital, Medical Department, Division of Hematology, Oncology and Tumor Immunology Berlin, Germany, 13353 Less <<
NCT00788580 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Withdrawn(Study was discontinu... More >>ed.) Less << - -
NCT01031875 Bladder Cancer ... More >> Transitional Cell Cancer of the Renal Pelvis and Ureter Urethral Cancer Less << Phase 2 Completed - Italy ... More >> Fondazione Istituto Nazionale dei Tumori Milan, Italy, 20133 Less <<
NCT00733304 Macular Degeneration PHASE2 COMPLETED 2009-09-09 GSK Investigational Site, Beve... More >>rly Hills, California, 90211, United States|GSK Investigational Site, Sacramento, California, 95841, United States|GSK Investigational Site, Winter Haven, Florida, 33880, United States|GSK Investigational Site, Indianapolis, Indiana, 46280, United States|GSK Investigational Site, Boston, Massachusetts, 02111, United States|GSK Investigational Site, Ann Arbor, Michigan, 48105, United States|GSK Investigational Site, Grand Rapids, Michigan, 49525, United States|GSK Investigational Site, Salt Lake City, Utah, 84132, United States|GSK Investigational Site, Sydney, New South Wales, 2145, Australia|GSK Investigational Site, Sydney, New South Wales, 2150, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Perth, Western Australia, 6009, Australia|GSK Investigational Site, Milano, Lombardia, 20132, Italy|GSK Investigational Site, Milano, Lombardia, 20157, Italy|GSK Investigational Site, Torino, Piemonte, 10122, Italy|GSK Investigational Site, Firenze, Toscana, 50134, Italy|GSK Investigational Site, Padova, Veneto, 35128, Italy Less <<
NCT00358384 Psoriasis Phase 1 Completed - France ... More >> GSK Investigational Site Paris, France, 75015 Less <<
NCT00561795 Primary Peritoneal Carcinoma ... More >> Tumor Epithelial Ovarian Cancer Uterine Disease Cervix Diseases Neoplasms, Ovarian Cancer Less << Phase 2 Completed - France ... More >> GSK Investigational Site Lyon Cedex 08, France, 69373 GSK Investigational Site Strasbourg, France, 67085 Germany GSK Investigational Site Marburg, Hessen, Germany, 35043 GSK Investigational Site Wiesbaden, Hessen, Germany, 65199 GSK Investigational Site Essen, Nordrhein-westfalen, Germany, 45122 Less <<
NCT01051700 Macular Degeneration Phase 1 Completed - United States, Minnesota ... More >> GSK Investigational Site Minneapolis, Minnesota, United States, 55404 United States, Texas GSK Investigational Site Austin, Texas, United States, 78744 United States, Washington GSK Investigational Site Tacoma, Washington, United States, 98418 Less <<
NCT01961583 Kidney Neoplasm Phase 2 Terminated(Termination of [18F... More >>]Fluciclatide production) Less << April 2016 Korea, Republic of ... More >> Asan Medical Center Seoul, Songpa-gu, Korea, Republic of, 138-736 Less <<
NCT00615524 Hormone-receptor Positive Brea... More >>st Cancer Less << Phase 2 Withdrawn(Cancelled Before Enr... More >>ollment) Less << November 2012 United States, California ... More >> GSK Clinical Trials Call Center San Francisco, California, United States, 94115 Less <<
NCT01514448 - Completed - -
NCT02570789 Clear-cell Metastatic Renal Ce... More >>ll Carcinoma Less << Phase 4 Active, not recruiting December 2018 Belgium ... More >> Cliniques universitaires Saint-Luc Brussel, Belgium, 1200 Less <<
NCT00561795 - Completed - -
NCT00540943 Neoplasms, Colorectal Phase 1 Completed - France ... More >> GSK Investigational Site Saint Herblain, France, 44805 GSK Investigational Site Toulouse, France, 31052 Less <<
NCT03091465 - Completed - -
NCT01134055 - Completed - -
NCT00388076 Neoplasms, Breast Phase 1 Completed - United States, New Jersey ... More >> GSK Investigational Site New Brunswick, New Jersey, United States, 08901 United States, Ohio GSK Investigational Site Cleveland, Ohio, United States, 44106 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 Less <<
NCT01134055 Macular Degeneration Phase 2 Completed - -
NCT00775307 Carcinoma, Non-Small-Cell Lung Phase 2 Phase 3 Completed - France ... More >> Annemasse - CH Ambilly, France, 74100 Bobigny - Hôpital Avicenne Bobigny, France, 93000 Bordeaux - Polyclinique Nord Bordeaux, France, 33300 Boulogne - Ambroise Paré Boulogne, France Béziers - CH Béziers, France, 34525 Caen - Centre François Baclesse Caen, France, 14000 Caen - CHU Côte de Nacre Caen, France, 14000 Clamart - Hôpital Percy Clamart, France, 92140 Clermont Ferrand - CHU Clermont Ferrand, France, 63000 Colmar - CH Colmar, France, 68000 Dax - CH Dax, France, 40107 Grenoble - CHU Grenoble, France, 38000 Le Mans - Centre Hospitalier Le Mans, France, 72000 Lille - Hôpital Calmette Lille, France, 59000 Mantes La Jolie - CH Mantes La Jolie, France, 78200 Marseille - Hôpital Sainte Marguerite Marseille, France, 13000 Metz - Clinique Claude Bernard Metz, France, 57000 Mont de Marsan - CH Mont de Marsan, France, 40000 Montpellier - Clinique Clémentville Montpellier, France, 34070 Montpellier - CHRU Montpellier, France, 34295 Moulins - CH Moulins, France, 03000 Nantes - Centre René Gauducheau Nantes, France, 44805 Nevers - CH Nevers, France, 58033 CHU Nîmes, France Orléans - CH Orléans, France, 45000 Paris - Saint Louis Paris, France, 75000 Paris - hôpital Saint-Antoine Paris, France, 75012 Paris - Hopital Tenon Paris, France, 75020 Pau - CH Pau, France, 64046 Centre Catalan d'Onologie Perpignan, France, 66000 Lyon Sud Pierre Bénite, France, 69495 Reims - CHU Reims, France, 51092 Rennes - CHU Rennes, France, 35033 Strasbourg - NHC Strasbourg, France, 63000 Thonon les bains - CH Thonon les bains, France, 74200 Toulon - HIA Toulon, France, 83000 Toulouse - CHU Larrey Toulouse, France Nancy - CHU Vandoeuvre lès Nancy, France, 54500 Vesoul - CHI Vesoul, France, 70000 Villejuif - Institut Gustave Roussy Villejuif, France, 94800 Less <<
NCT00678977 Lung Cancer, Non-Small Cell Phase 1 Completed - Germany ... More >> GSK Investigational Site Essen, Nordrhein-Westfalen, Germany, 45122 United Kingdom GSK Investigational Site Newcastle Upon Tyne, Northumberland, United Kingdom, NE4 6BE Less <<
NCT01362348 Macular Degeneration Phase 2 Terminated(Lack of efficacy id... More >>entified during a preliminary analysis) Less << - United States, Arizona ... More >> GSK Investigational Site Phoenix, Arizona, United States, 85014 United States, Florida GSK Investigational Site Miami, Florida, United States, 33143 GSK Investigational Site Winter Haven, Florida, United States, 33880 United States, Georgia GSK Investigational Site Decatur, Georgia, United States, 30030 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Michigan GSK Investigational Site Grand Rapids, Michigan, United States, 49525 United States, Ohio GSK Investigational Site Cleveland, Ohio, United States, 44195 United States, Texas GSK Investigational Site Austin, Texas, United States, 78705 GSK Investigational Site Houston, Texas, United States, 77030 France GSK Investigational Site Paris cedex 10, France, 75475 GSK Investigational Site Paris cedex 12, France, 75571 Germany GSK Investigational Site Muenchen, Bayern, Germany, 80336 GSK Investigational Site Bonn, Nordrhein-Westfalen, Germany, 53127 GSK Investigational Site Muenster, Nordrhein-Westfalen, Germany, 48145 GSK Investigational Site Leipzig, Sachsen, Germany, 04103 Less <<
NCT00256880 Carcinoma, Renal Cell PHASE2 COMPLETED 2025-12-05 GSK Investigational Site, Litt... More >>le Rock, Arkansas, 72205, United States|GSK Investigational Site, Boston, Massachusetts, 02115, United States|GSK Investigational Site, Durham, North Carolina, 27710, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19104, United States|GSK Investigational Site, Seattle, Washington, 98109, United States|GSK Investigational Site, East Melbourne, Victoria, 3002, Australia|GSK Investigational Site, Melbourne, Victoria, 3004, Australia|GSK Investigational Site, Melbourne, Victoria, 3050, Australia Less <<
NCT01362348 - Terminated(Lack of efficacy id... More >>entified during a preliminary analysis) Less << - -
NCT01512186 - Unknown December 2014 United Kingdom ... More >> Basildon and Thurrock University Hospitals NHS Foundation Trust Basildon, United Kingdom University Hospitals Coventry & Warwickshire NHS Trust Coventry, United Kingdom The Beatson West of Scotland Cancer Centre Glasgow, United Kingdom Barts and London Hospital NHS Trust London, United Kingdom Oncology & Clinical Haematology Trials Unit, Royal Free Hospital London, United Kingdom Oncology & Haematology Clinical Trials Unit, Guy's Hospital London, United Kingdom Department of Oncology Oxford Cancer Centre Oxford, United Kingdom Southampton General Hospital Southampton, United Kingdom Southend University Hospital Trust Southend, United Kingdom Less <<
NCT00463320 Macular Degeneration ... More >> Age-related Macular Degeneration Less << Phase 1 Completed - United States, North Dakota ... More >> GSK Investigational Site Fargo, North Dakota, United States, 58104 United States, Texas GSK Investigational Site Austin, Texas, United States, 78744 Less <<
NCT00992121 Carcinoma, Renal Cell Phase 1 Completed - United Kingdom ... More >> GSK Investigational Site Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ Less <<
NCT03139331 Sarcoma Phase 1 Recruiting November 30, 2019 United States, California ... More >> UCSF Benioff Children's Hospital, Oakland Recruiting Oakland, California, United States, 94609 Contact: Jennifer Michlitsch, MD    510-428-3372    jmichlitsch@mail.cho.org    Principal Investigator: Jennifer Michlitsch, MD          UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94158 Contact: Kieuhoa Vo, MD, MAS    415-476-3831    kieuhoa.vo@ucsf.edu    Principal Investigator: Kieuhoa Vo, MD, MAS          United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Steven DuBois, MD    617-632-5640    steve_dubois@dfci.harvard.edu    Principal Investigator: Steven DuBois, MD Less <<
NCT01666418 Melanoma Phase 2 Completed - Switzerland ... More >> University Hospital Zurich, Division of Dermatology Zurich, Switzerland Less <<
NCT00459862 - Completed - -
NCT01931098 Glioblastoma ... More >>Glioblastoma Multiforme Gliosarcoma Brain Neoplasms Central Nervous System Neoplasms Less << Phase 2 Active, not recruiting September 1, 2020 United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01221506 Carcinoma, Renal Cell Early Phase 1 Completed - United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT01644825 Ovarian Cancer Phase 2 Completed - Italy ... More >> Osp. Regionale Mulli Acquaviva delle Fonti, Italy Ospedale San donato Arezzo, Italy A.O. G. Rummo Benevento, Italy Ospedale Bellaria Bologna, Italy Ospedale Senatore Antonio Perrino Brindisi, Italy A.O. Garibaldi Nesimadi Catania Catania, Italy Ospedale Civile di Faenza Faenza, Italy A.O.U. Arcispedale Sant'Anna di Ferrara Ferrara, Italy Ospedale Fabrizio Spaziani della ASL di Frosinone Frosinone, Italy Ospedale Umbero I Lugo, Italy Istituto Nazionale Tumori Milano, Italy A.O. Univeristaria Policlinico Modena, Italy Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico Napoli, Italy, 80131 Seconda Universita di Napoli Napoli, Italy Ospedale Silvestrini Perugia, Italy Ospedale S. Maria delle Croci AUSL di Ravenna Ravenna, Italy A.O. Bainchi Melacrino Morelli Osp. Riuniti Reggio Calabria, Italy Ospedale degli Infermi, P.O. Ospedale Civile Rimini, Italy Policlinico Umberto I Roma, Italy Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore Roma, Italy Less <<
NCT00459862 Advanced Malignant Mesotheliom... More >>a Localized Malignant Mesothelioma Recurrent Malignant Mesothelioma Less << Phase 2 Completed - United States, Minnesota ... More >> North Central Cancer Treatment Group Rochester, Minnesota, United States, 55905 Less <<
NCT00367679 Non-Small Cell Lung Cancer|Lun... More >>g Cancer, Non-Small Cell Less << PHASE2 COMPLETED 2025-04-08 GSK Investigational Site, Duar... More >>te, California, 91010, United States|GSK Investigational Site, Rancho Mirage, California, 92270, United States|GSK Investigational Site, Aurora, Colorado, 80045, United States|GSK Investigational Site, Newark, Delaware, 19718, United States|GSK Investigational Site, Miami, Florida, 33136, United States|GSK Investigational Site, Chicago, Illinois, 60612, United States|GSK Investigational Site, Paramus, New Jersey, 07652, United States|GSK Investigational Site, Flushing, New York, 11355, United States|GSK Investigational Site, New York, New York, 10016, United States|GSK Investigational Site, New York, New York, 10065, United States|GSK Investigational Site, Jerusalem, 91120, Israel|GSK Investigational Site, Barcelona, 08035, Spain Less <<
NCT01377298 Head and Neck Squamous Cell Ca... More >>rcinoma Less << PHASE2 UNKNOWN 2025-05-14 National Taiwan University Hos... More >>pital, Taipei, 100, Taiwan Less <<
NCT00281632 Peritoneal Cancer|Ovarian Canc... More >>er|Neoplasms, Ovarian|Fallopian Tube Cancer Less << PHASE2 COMPLETED 2025-10-10 GSK Investigational Site, Atla... More >>nta, Georgia, 30342, United States|GSK Investigational Site, Austin, Texas, 78731, United States|GSK Investigational Site, Bedford, Texas, 76022, United States|GSK Investigational Site, Dallas, Texas, 75246, United States|GSK Investigational Site, Fort Worth, Texas, 76104, United States|GSK Investigational Site, Randwick, New South Wales, 2031, Australia|GSK Investigational Site, Herston, Queensland, 4029, Australia|GSK Investigational Site, Melbourne, 3084, Australia|GSK Investigational Site, Singapore, 119074, Singapore|GSK Investigational Site, Singapore, 229899, Singapore Less <<
NCT01262014 Platinum-resistant Advanced Ov... More >>arian Cancer Less << PHASE2 COMPLETED 2025-12-15 H. Alcorcón, Alcorcón, 28922, ... More >>Spain|H. de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|H Vall d'Hebron, Barcelona, 08035, Spain|H. Clínic Barcelona, Barcelona, 08036, Spain|H Reina Sofía Cordoba, Cordoba, 14004, Spain|Intitut Català d' Oncolgia L' Hospitalet, Hospitalet de LLobregat, 08907, Spain|HGU Gregorio Mara?ón, Madrid, 28007, Spain|Centro Oncológico MD Anderson Spain, Madrid, 28034, Spain|H Ramón y Cajal de Madrid, Madrid, 28034, Spain|H Madrid. Centro Integral Oncológico Clara Campal, Madrid, 28250, Spain|H de Sant Joan de Deu, Manresa, 08009, Spain|H Morales Meseguer, Murcia, 30008, Spain|H Son Dureta, Palma de Mallorca, 07003, Spain|H Son Llatzer, Palma de Mallorca, 07003, Spain|H. Parc Taulí, Sabadell, 08208, Spain|H Marqués de Valdecilla, Santander, 39008, Spain|H La Fe de Valencia, Valencia, 46009, Spain|Instituto Valenciano de Oncología, Valencia, 46009, Spain|H General de Valencia, Valencia, 46014, Spain|H Miguel Servet, Zaragoza, 50009, Spain Less <<
NCT01154062 Macular Degeneration PHASE1 COMPLETED 2011-04-29 GSK Investigational Site, Beve... More >>rly Hills, California, 90211, United States|GSK Investigational Site, Sacramento, California, 95819, United States|GSK Investigational Site, Sacramento, California, 95841, United States|GSK Investigational Site, Winter Haven, Florida, 33880, United States|GSK Investigational Site, Indianapolis, Indiana, 46290, United States|GSK Investigational Site, Grand Rapids, Michigan, 49525, United States|GSK Investigational Site, Austin, Texas, 78705, United States Less <<
NCT04462445 Metastatic Renal Cell Carcinom... More >>a Less << PHASE2 COMPLETED 2017-02-08 -
NCT02378142 Uterine Leiomyosarcoma PHASE2 WITHDRAWN - -
NCT00612456 Macular Degeneration PHASE2 COMPLETED 2009-06-17 GSK Investigational Site, Tucs... More >>on, Arizona, 85704, United States|GSK Investigational Site, Beverly Hills, California, 90211, United States|GSK Investigational Site, Pasadena, California, 91105, United States|GSK Investigational Site, Sacramento, California, 95841, United States|GSK Investigational Site, Fort Lauderdale, Florida, 33334, United States|GSK Investigational Site, Winter Haven, Florida, 33880, United States|GSK Investigational Site, Indianapolis, Indiana, 46280, United States|GSK Investigational Site, Boston, Massachusetts, 02111, United States|GSK Investigational Site, Ann Arbor, Michigan, 48105, United States|GSK Investigational Site, Grand Rapids, Michigan, 49525, United States|GSK Investigational Site, Toms River, New Jersey, 08755, United States|GSK Investigational Site, Winston-Salem, North Carolina, 27157, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15213, United States|GSK Investigational Site, Austin, Texas, 78705, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, Salt Lake City, Utah, 84132, United States|GSK Investigational Site, Sydney, New South Wales, 2145, Australia|GSK Investigational Site, Sydney, New South Wales, 2150, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Perth, Western Australia, 6009, Australia|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Trieste, Friuli-Venezia-Giulia, 34129, Italy|GSK Investigational Site, Milano, Lombardia, 20132, Italy|GSK Investigational Site, Milano, Lombardia, 20157, Italy|GSK Investigational Site, Torino, Piemonte, 10122, Italy|GSK Investigational Site, Firenze, Toscana, 50134, Italy|GSK Investigational Site, Padova, Veneto, 35128, Italy Less <<
NCT00827372 Lymphedema PHASE2 COMPLETED 2025-07-10 Indiana University Melvin and ... More >>Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States Less <<
NCT01099540 Neuroendocrine Tumor PHASE2 COMPLETED 2025-03-13 Samsung Cancer Center, Seoul, ... More >>Korea, Republic of Less <<
NCT03850730 Hereditary Hemorrhagic Telangi... More >>ectasia|Epistaxis Less << PHASE1|PHASE2 NOT_YET_RECRUITING 2025-12-31 -
NCT02282579 Metastatic Renal Cell Carcinom... More >>a Less << COMPLETED 2025-04-15 Hospital Son Espases, Palma De... More >> Mallorca, Mallorca, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Vall d' Hebron, Barcelona, Spain|Hospital San Pedro de Alcántara, Caceres, Spain|Hospital G U de Ciudad Real, Ciudad Real, Spain|Hospital Reina Sofía, Cordoba, Spain|Hospital Universitario de Donostia, Donostia, Spain|Hospital San Cecilio, Granada, Spain|Hospital General Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain|Hospital de León, León, Spain|Hospital San Pedro Logro?o, Logro?o, Spain|Hospital Lucus Augusti, Lugo, Spain|Hospital Gregorio Mara?on, Madrid, 28007, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Quirón, Madrid, Spain|Hospital U Puerta de Hierro Majadahonda, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Provincial de Pontevedra, Pontevedra, Spain|Hospital Clínico Universitario Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain|Hospital Marques de Valdecilla, Santander, Spain|Hospital Ntra. Sra. De Valme, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clínico de Valencia, Valencia, Spain|Hospital Gral Universitario Valencia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|IVO Valencia, Valencia, Spain|Hospital Rio Hortega, Valladolid, Spain|CHUVI ( Vigo), Vigo, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.43mL

2.29mL

1.14mL

22.86mL

4.57mL

2.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories